Document:

EX-10.7

 Exhibit 10.7 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. 
 STOCK PURCHASE AGREEMENT 

BY AND BETWEEN 
 ATAI US
2, INC. 
 AND 

JONATHAN SPORN 
 DATED
AS OF NOVEMBER 5, 2018 
  

 STOCK PURCHASE AGREEMENT 

THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 5, 2018 by and among ATAI US 2,
Inc., a Delaware corporation (the “Buyer”) and Dr. Jonathan Sporn, an individual (“Seller”). 

WHEREAS, as of the date hereof, Seller, together with Mr. Jay Kranzler (“Kranzler”) collectively own one hundred percent
(100%) of the issued and outstanding stock (the “Shares”) of Perception Neuroscience, Inc., a Delaware corporation (the “Company”), in the amounts set forth on Section 4.3(a) of the Disclosure Schedules (as
defined herein); 
 WHEREAS, immediately prior to the execution and delivery of this Agreement, and as a condition and inducement to the
willingness of Buyer to enter into this Agreement, Seller and Kranzler are entering into the rollover agreement (in the form attached hereto as Exhibit B, the “Rollover Agreement”) in connection with the transactions
contemplated hereby; 
 WHEREAS, immediately prior to the Closing (as hereinafter defined), (a) Seller and Kranzler shall contribute to
Parent (as hereinafter defined) a portion (in the case of Seller) or all (in the case of Kranzler) of their Shares (the “Rollover Shares”) in exchange for the Parent Shares (as hereinafter defined) as set forth opposite
Seller’s and Kranzler’s respective names on Exhibit A hereto (the “Rollover”), (b) ATAI Life Sciences AG will make a contribution of cash to Parent in exchange for capital stock of Parent, and (c) the
contributions in clauses (a) and (b) are intended to be characterized by Seller, Kranzler and Parent as a single interrelated transaction that is treated as an exchange described in Section 351(a) of the Code; 

WHEREAS, immediately after the Rollover and immediately before the purchase of Shares by Buyer from Seller pursuant to this Agreement, Parent
shall contribute the Rollover Shares to Buyer; and 
 WHEREAS, prior to or concurrently with, as applicable, the execution and delivery of
this Agreement, and as a condition and inducement to the willingness of the parties hereto to enter into this Agreement, (a) ATAI Life Sciences AG, Arcos Ventures SPV, LLC, Parent and the Seller have executed and delivered the Stockholder
Agreement (as defined herein); (b) Parent and Dr. Jonathan Sporn have executed and delivered the Employment Agreement (as defined herein); and (c) Parent and Kranzler have executed the Consulting Agreement; 

WHEREAS, at the Closing, Buyer shall purchase from Seller, and Seller shall sell to Buyer, all of Seller’s Shares other than
Seller’s Rollover Shares (the “Purchased Shares”), subject to the terms and conditions set forth in this Agreement; 

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto intending to be legally bound do hereby agree as follows: 

 

 ARTICLE I. 

DEFINITIONS. 
 1.1.
Defined Terms. As used in this Agreement, the following terms have the meanings set forth below: 
 (a) “Affiliate”
of any particular Person shall mean any other Person Controlling, Controlled by or under common Control with such Person. 
 (b)
“Annual Revenue” has the meaning set forth in Section 2.3(b)(ii). 
 (c) “Anti-Bribery Laws” shall
mean (i) the U.S. Foreign Corrupt Practices Act of 1977, as amended, the Federal Anti-kickback Statute (42 U.S.C. § 1320a-7(b)), Federal False Claims Act (31 U.S.C. §§ 3729,
et seq.), and related or similar federal or state statutes, (ii) any applicable Law enacted in any jurisdiction in connection with or arising under the OECD Convention on Combating Bribery of Foreign Public Officials in International Business
Transactions, (iii) or any other applicable Law of similar purpose and scope to the Laws in the preceding clauses (i) and (ii) in any jurisdiction, including books and records or accounting controls offenses relating directly or indirectly
to a bribe. 
 (d) “Basket” has the meaning set forth in Section 8.4(a). 

(e) “Books and Records” shall mean any and all business records, financial books and records, minute books, share ledgers and
any other records required to be kept pursuant to applicable Law. 
 (f) “Business Day” shall mean a day other than a
Saturday, Sunday or any other day on which banks are required or authorized to close in New York City. 
 (g) “Buyer” has
the meaning set forth in the Recitals. 
 (h) “Buyer Indemnitee” has the meaning set forth in Section 8.1(a). 

(i) “Buyer Rights Chain Group” means (a) Buyer, the Company and their respective Affiliates and (b) any Person to
which, after the Closing Date, the Company Intellectual Property covering any Product is licensed, sublicensed, assigned or transferred by Buyer, the Company or their respective Affiliates directly or through one or more intermediaries (i.e.,
whether through one or more assignments, one or more levels of licenses and/or sublicenses, any combination thereof or otherwise) in a manner which provides such Person with the right to commercially sell such Product anywhere in the world. 

(j) “Chiba License” means that certain License Agreement entered into as of August 14, 2017, as amended, by and between
the National University Corporation Chiba University and the Company. 

  
 2 

 (k) “Closing Liabilities” shall mean the accrued but unpaid Indebtedness of
the Company as of the Closing, excluding, (i) any item of Indebtedness also constituting Company Transaction Expenses and (ii) those items set forth on Schedule 1.1-A hereto. 

(l) “Code” means Internal Revenue Code of 1986, as amended 

(m) “Company Intellectual Property” shall mean (i) all Intellectual Property owned by the Company, including all of the
Patents, Trademarks and Internet domain names set forth in Section 4.10(a) of the Disclosure Schedules and (ii) all Intellectual Property that is not owned by the Company but that is licensed to the Company (or for which there is an option
to obtain a license for the Company) and is material to the conduct of the Company’s business as currently conducted, including the intellectual property licensed under the Chiba License. 

(n) “Company Tax Returns” has the meaning set forth in Section 6.4(b). 

(o) “Company Transaction Expenses” shall mean, without duplication, the unpaid amount at Closing of any out-of-pocket fees, costs and expenses of counsel, accountants, consultants and investment bankers to the Company incurred by the Company in connection with the drafting,
negotiation, execution and delivery of this Agreement and the carrying out of the provisions of this Agreement and the consummation of each of the transactions contemplated hereby that are required to be paid by or on behalf of the Company, in each
case, in respect of services rendered for periods ending on or prior to the Closing, and such other costs and expenses set forth on Schedule 1.1-B hereto; provided that,
in no event shall the Company Transaction Expenses together with the Closing Liabilities exceed Six Hundred Thousand Dollars ($600,000). 

(p) “Consulting Agreement” means that certain Consulting Agreement between the Parent and Kranzler in the term of
Exhibit C hereto. 
 (q) “Contingent Payments” has the meaning set forth in
Section 2.3(b)(ii). 
 (r) “Control” means (including, with correlative meanings, “controlled by” and
“under common control with”), with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting
securities, by Contract or otherwise. 
 (s) “Copyrights” shall mean all rights in all works of authorship and copyrightable
works and mask works, all registered and unregistered copyrights in both published and unpublished works, and all applications, registrations, and renewals in connection therewith, including computer software applications or programs (including
source and object code), databases and other compilations, and related documentation. 
 (t) “Current Company Business”
shall mean as of the date hereof, the business of the Company as it is being conducted on the date hereof or as it is planned to be conducted, as of the date hereof or as it is reasonably expected to be conducted as of the Closing Date, in each
case, solely with respect to the development, manufacture and commercialization of the Lead Product or any Product containing the Lead Product. 

  
 3 

 (u) “Disclosure Schedules” shall mean the disclosure schedules attached
hereto being delivered by the Seller on the date hereof which, subject to Section 9.10, are divided into sections and subsections that correspond to the sections and subsections of ARTICLE III and ARTICLE IV, as applicable.

 (v) “Employment Agreement” means that certain Employment Agreement between Parent and Dr. Jonathan Sporn, in the
form of Exhibit D hereto. 
 (w) “Environmental Laws” shall mean all international, foreign, federal, state and local
statutes, Laws, regulations, ordinances, orders, principles of common law, and similar provisions having the force or effect of Law, in each case applicable to the Company, its assets or its operations, including any judicial and administrative
interpretations of the foregoing, relating to or which govern: (i) public health, or pollution or protection, preservation or restoration of the environment (including air, water vapor, surface water, groundwater, drinking water supply, surface
land, subsurface land, plant and animal life or any other natural resource); (ii) the existence, cleanup, removal and/or remediation of contamination or threat of contamination on or about the Leased Real Property; (iii) the exposure to, or the
use, storage, recovery, recycling, treatment, generation, transportation, processing, handling, labeling, production, release, disposal, removal, emission or discharge of any Hazardous Materials (including building materials) or (iv) safety
issues (including human and occupational safety and health). 
 (x) “ERISA” means the Employee Retirement Income Security
Act of 1974 as amended, or any successor federal Law, and the rules and regulations promulgated thereunder, all as the same may from time to time be in effect. 

(y) “FDA” means the U.S. Food and Drug Administration. 

(z) “Fundamental Representations” shall mean the representations and warranties set forth in Section 4.1 (Organization
and Power; Investments), Section 4.3 (Capitalization; Subsidiaries) and Section 4.22 (No Brokers). 
 (aa) “Governmental
Authority” shall mean any government or any court, arbitral tribunal, administrative agency or commission or other governmental or other regulatory authority, instrumentality or agency, whether federal, state, local, domestic or foreign.

 (bb) “Hazardous Materials” shall mean any waste or other substance that is listed, defined, designated, or classified as
hazardous, dangerous, radioactive, or toxic or a pollutant or a contaminant under or pursuant to, or otherwise regulated by, any Environmental Law including any mixture or solution thereof, and specifically including petroleum and all derivatives
thereof or synthetic substitutes therefor and asbestos or asbestos-containing materials. 
 (cc) “Indebtedness” shall mean,
without duplication, (i) all obligations of the Company for borrowed money (including accrued and unpaid interest), and prepayment and other penalties (including any consent fees that must be paid in connection with an early termination)
(specifically excluding trade or accounts payable and other ordinary course accrued expenses, unless otherwise falling within clauses (ii) through (viii) of this definition), (ii) any obligations of the Company evidenced by bonds, debentures,
notes or other similar instruments, including factoring arrangements or asset securitizations, (iii) any obligations of the Company to pay the 

  
 4 

 
deferred purchase price of property or assets (specifically excluding trade or accounts payable and other ordinary course accrued expenses), (iv) any obligations of the Company for capitalized
liabilities as lessee under capitalized leases, (v) any indebtedness of the Company created or arising under any conditional sale or other title retention agreement with respect to acquired property, (vi) any obligations of the Company for
any change of control payments, bonuses or other consideration (including any deferred compensation) to officers, directors, employees or consultants of the Company, in each case, that become payable as a result of the Closing of the transactions
contemplated by this Agreement (but excluding any such obligations occurring or arising after the Closing (e.g., any so-called “double-trigger” obligation arising from the termination, or
constructive termination, of any employee or consultant after the Closing), (vii) any unreimbursed drawings, or amounts subject to initiated claims (and not the face amount specified, unless fully subject to such claims) of the Company under letters
of credit, letters of guarantee, surety bonds or similar facilities or obligations in respect of bankers acceptances and (viii) any guaranty by the Company of any of the foregoing. 

(dd) “Indemnitee” has the meaning set forth in Section 8.2(a). 

(ee) “Intellectual Property” shall mean: (i) all inventions and discoveries (whether patentable or unpatentable and
whether or not reduced to practice), all improvements thereto, and all Patents; (ii) all Trademarks; (iii) all Copyrights; (iv) all Trade Secrets; (v) and all rights in Internet websites and Internet domain names and world wide
web addresses;. 
 (ff) “Inventory” shall mean all inventories of the Company’s product candidates, including
inventories of work-in-process, finished goods, raw materials, supplies, equipment, parts, labels and packaging (including rights and interests in goods in transit,
consigned inventory, inventory sold on approval and rental inventory) and all returned products, samples and obsolete and non-salable inventory. 

(gg) “Knowledge,” “to the Knowledge of” or words of like import shall mean, with respect to the Seller, the
actual knowledge of Seller, and the knowledge that such person would reasonably be expected to have after making reasonable (i.e., consistent with the role held by such Person as a director and officer of the Company, as applicable, and consistent
with past practice) inquiry with respect to the relevant matter. 
 (hh) “Kranzler” has the meaning set forth in the
Recitals. 
 (ii) “Laws” shall mean all constitutions, codes, laws, statutes, ordinances, rules, rulings, regulations,
orders, charges, directives, determinations, treaties, executive orders, writs, judgments, injunctions, decrees, restrictions, requirements, guidelines, guidance documents, standards, enforcement policies, or similar pronouncements, in each case, of
any Governmental Authority. 
 (jj) “Liability” or “Liabilities” shall mean any material obligations or
liabilities of any kind whatsoever (whether accrued, absolute, contingent, unliquidated or otherwise, whether or not known, whether due or to become due and regardless of when asserted). 

  
 5 

 (kk) “Liens” shall mean, other than any Permitted Lien, any mortgage,
pledge, security interest, conditional sale or other title retention agreement, encumbrance, lien, easement, option, debt, charge or any similar restriction of any kind. 

(ll) “Material Adverse Effect” means any material adverse effect on the business, condition (financial or otherwise),
operations, results of operations, employee relations, customer or supplier relations or assets or liabilities of the Company. 
 (mm)
“Milestone” shall mean the first date upon which the following have occurred: (A) that the Lead Product shall have met the primary endpoint in the first placebo controlled clinical study which includes multiple dose levels of
the Lead Product Candidate and which is designed to be the efficacy basis for the FDA End of Phase 2 meeting or equivalent meeting with regulatory authorities outside the U.S., together with (B) the occurrence of the FDA End of Phase 2 meeting
with respect to the Lead Product Candidate. 
 (nn) “Milestone Payment” shall mean [***] (USD [***]). 

(oo) “Order” shall mean a temporary restraining order, preliminary or permanent injunction or other order or decree of a court
of competent jurisdiction or other Governmental Authority. 
 (pp) “Patents” shall mean: (i) all patents, including all
issued patents, reissued or reexamined patents and revivals of patents; (ii) all utility models, industrial designs and certifications of invention; (iii) all patent applications, utility model applications, industrial design applications
and applications for certificates of invention, including all published and unpublished patent applications, nonprovisional and provisional patent applications, reissue applications, continuation applications, continuation-in-part applications, divisions or divisional applications; and, with respect to any of the foregoing listed in clauses (i) through (iii), all rights, priorities, renewals, reissues,
reexaminations, certificates, registrations and extensions thereof, regardless of the country or jurisdiction filed or formal name. 
 (qq)
“Parent” shall mean Perception Neuroscience Holdings, Inc., a Delaware corporation. 
 (rr) “Parent Shares”
shall mean the shares of common stock of the Parent, par value $0.0001 per share. 
 (ss) “Payoff Letters” shall mean
letters setting forth, or other written evidence of, the amount or amounts required to be paid to the Persons to whom the Company is obligated in respect of Closing Liabilities or, to the extent set forth on Schedule (ss) hereto, Company
Transaction Expenses (including accrued interest and any prepayment fees or penalties or other amounts due as a result of the consummation of the transactions contemplated hereby), to cause such obligations to be paid and satisfied in full and all
Liens securing such obligations, if any, to be released. 

  
 6 

 (tt) “Permits” shall mean all licenses, permits, certificates, clearances,
exemptions, approvals, registrations, consents and other authorizations, including those issued by any Governmental Authority (including the FDA), that are required for the research, development, manufacture, distribution, marketing, use and sale of
the products of the Company. 
 (uu) “Permitted Lien” shall mean (a) Liens for Taxes not yet due and payable or being
contested in good faith by appropriate procedures and for which reserves have been made to the extent required by GAAP; (b) statutory landlord’s, mechanic’s or other similar Liens arising or incurred in the ordinary course of
business; (c) easements, rights of way, zoning ordinances and other similar encumbrances affecting real property; or (d) liens arising under original purchase price conditional sales contracts and equipment leases with third parties
entered into in the ordinary course of business. 
 (vv) “Person” shall mean any individual, sole proprietorship,
partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity or Governmental Authority. 

(ww) “Pre-Closing Taxes” means (a) Taxes of or imposed on or with respect to the
Company or any of its Subsidiaries for a Pre-Closing Tax Period (including the portion of any Straddle Period ending on the Closing Date as determined based on the principles of Section 6.4(c)); (b) any
Taxes of any other Person for which the Company or its Subsidiary is liable as a result of having been a member of an affiliated, consolidated, combined or unitary group on or prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or any analogous or similar state, local, or non-U.S. Law; (c) Taxes of any Person imposed on the Company or its Subsidiary as a transferee or
successor where the relationship giving rise to the liability on the part of the Company or its Subsidiary existed or arose on or prior to the Closing Date, or by Contract (other than any Contract entered into in the ordinary course of business and
the primary subject matter of which is not Taxes) entered into prior to the Closing, in each case, to the extent such Taxes relate to an event or occurrence prior to the Closing and (d) any Taxes imposed on Buyer or an Affiliate of Buyer as a
result of amounts required to be included in income by Buyer or its Affiliates under Section 951 of the Code or under Section 951A of the Code, in each case, for the taxable period in which the Closing occurs and that is attributable,
based on an interim closing of the books at Closing, to the Pre-Closing Tax Period (or portion thereof) with respect to the Company or any of its Subsidiaries; provided, that
Pre-Closing Taxes shall not include any Taxes that (i) are attributable to any election under Section 338 or 336(e) of the Code with respect to transactions contemplated by this Agreement;
(ii) are taken into account in the calculation of Closing Liabilities and reduce the Closing Cash Consideration; (iii) arise due to actions taken by Buyer on the Closing Date after the Closing that are outside of the ordinary course of
business, (iv) Buyer has agreed to pay pursuant to Section 6.4(a) or (v) arise in connection with any breach by Parent, Buyer or any of their Affiliates of Section 6.4(e). 

(xx) “Pre-Closing Tax Period” means any tax period ending on or before the Closing
Date and the portion of a Straddle Period ending on the Closing Date. 
 (yy) “Pro-Rata
Share” shall mean, with respect to Seller, 80%. 
 (zz) “Product” means any product in any form or formulation
containing any Product Candidate, alone or in combination with one or more other active agents. 

  
 7 

 (aaa) “Product Candidates” means
(i) R-Ketamine (the “Lead Product Candidate”) and (ii) any other pharmaceutical product candidate the manufacture, use, sale or offer for sale of which is covered by any Patent in
the Company Intellectual Property. 
 (bbb) “Provider” shall mean any manufacturer, sales agent, representative,
distributor, reseller, middleman, marketer, broker, franchisor or similar Person who is entitled to receive commissions, fees or markups related to the provision or resale of goods or services of the Company. 

(ccc) “Purchased Shares” has the meaning set forth in the Recitals. 

(ddd) “Related Companies” shall mean the Affiliates of the Company (other than any Subsidiary of the Company). 

(eee) “Release” shall have the meaning set forth in Section 4.14. 

(fff) “Released Party” shall have the meaning set forth in Section 6.7. 

(ggg) “Released Matters” shall have the meaning set forth in Section 6.7. 

(hhh) “R-Ketamine” shall mean R-ketamine, also
referred to as arketamine, including the pure enantiomer, as well as combinations of R-ketamine with other compounds, including a racemic mixture. 

(iii) “Rollover Agreement” has the meaning set forth in the Recitals. 

(jjj) “Rollover Shares” has the meaning set forth in the Recitals. 

(kkk) “Rollover Value” has the meaning set forth in the Recitals. 

(lll) “Royalty Payment” shall have the meaning set forth in Section 2.3(b)(i). 

(mmm) “Royalty Report” shall have the meaning set forth in Section 2.3(b)(iv). 

(nnn) “Royalty Term” shall have the meaning set forth in Section 2.3(b)(ii). 

(ooo) “Seller” has the meaning set forth in the Recitals. 

(ppp) “Seller Indemnitee” has the meaning set forth in Section 8.2(a). 

(qqq) “Seller Fraud” means with respect to Seller, fraud with an intent to deceive, with malice or similar intent (but
excluding any fraud committed without such intent (for instance, with only negligence or recklessness)), committed by Seller with respect to any of the representations and warranties or covenants of Seller under this Agreement or under any
Exhibit or Schedule required to be delivered by Seller pursuant to the terms of this Agreement. 
 (rrr) “Shares”
has the meaning set forth in the Recitals. 
 (sss) “Straddle Period” has the meaning set forth in Section 6.4(b). 

  
 8 

 (ttt) “Subject Business” has the meaning set forth in Section 6.1(a).

 (uuu) “Stockholder Agreement” means that certain Stockholder Agreement by and among Parent, Seller, Kranzler, ATAI Life
Sciences AG and Arcos Ventures SPV, LLC in the form of Exhibit E hereto. 
 (vvv) “Subsidiary” means with respect to
any specified Person, any other Person (a) whose board of directors or similar governing body, or a majority thereof, may presently be directly or indirectly elected or appointed by such specified Person, (b) whose management decisions and
corporate actions are directly or indirectly subject to the present Control of such specified Person, and/or (c) whose voting securities are 50% or more owned, directly or indirectly, by such specified Person. 

(www) “Tax” means any net or gross income, net or gross receipts, net or gross proceeds, capital gains, capital stock, sales,
use, user, leasing, lease, transfer, natural resources, premium, ad valorem, value added, franchise, profits, gaming, license, capital, withholding, payroll or other employment, estimated, goods and services, severance, excise, stamp, fuel, interest
equalization, registration, recording, occupation, premium, turnover, personal property (tangible and intangible), real property, unclaimed or abandoned property, alternative or add-on, windfall or excess
profits, environmental (including Section 59A of the Code as in effect for Tax years beginning prior to January 1, 2018), social security, disability, unemployment or other tax or customs duties or amount in the nature of a tax imposed by
(or otherwise payable to) any Taxing Authority, or any interest, any penalties, additions to tax or additional amounts assessed, imposed, or otherwise due or payable under applicable Laws with respect to taxes, in each case, whether disputed or not.

 (xxx) “Tax Claim” has the meaning set forth in the Section 6.4(d). 

(yyy) “Tax Return” means any return, declaration, report, claim for refund, or information return or statement relating to
Taxes, including any schedule or attachment thereto, and any amendments thereto, submitted to (or required under applicable Laws to be submitted to) a Taxing Authority. 

(zzz) “Taxing Authority” shall mean any branch, office, department, agency, instrumentality, court, tribunal, officer,
employee, designee, representative, or other Person that is acting for, on behalf of, or as a part of, any foreign or domestic government (or any political subdivision thereof) that is engaged in or has any power, duty, responsibility or obligation
relating to the legislation, promulgation, interpretation, enforcement, regulation, monitoring, supervision or collection of, or any other activity relating to, any Tax. 

(aaaa) “Trade Secrets” shall mean information, including discoveries, concepts, ideas, research and development, know-how, formulae, inventions, compositions, manufacturing and production processes and techniques, technical data, procedures, designs, drawings, specifications, databases, and other proprietary or confidential
information, including customer lists, supplier lists, pricing and cost information, and business and marketing plans and proposals, in each case to the extent such information is protectable as a trade secret under applicable Law. 

  
 9 

 (bbbb) “Trademarks” shall mean all registered and unregistered trademarks,
service marks, trade dress, logos, trade names, corporate names, brand names and assumed fictional business names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith,
and all applications, registrations, and renewals in connection therewith. 
 (cccc) “Transaction Deductions” means all Tax
deductions available to the Company resulting from or attributable to (i) the repayment at or prior to Closing of Company Liabilities and the payment at or prior to Closing of any related fees, expenses or interest, and (ii) Company
Transaction Expenses (including legal, financial advisory, accounting, investment banking and any other fees and expenses of the Company economically borne by the Seller in connection with the transactions contemplated). Any success-based fees of
the Company shall be treated as deductible in accordance with Rev. Proc. 2011-29. 
 ARTICLE II.

 THE CLOSING; PURCHASE AND SALE. 

2.1. Purchase of Shares. 

(a) At the Closing, subject to the terms and conditions of this Agreement, the Buyer shall purchase and accept from Seller all of the Purchased
Shares owned by Seller, and Seller shall sell, transfer and deliver to the Buyer Seller’s Purchased Shares. 
 (b) In consideration for
the sale and purchase of the Purchased Shares, pursuant to the terms and conditions contained herein, the aggregate consideration payable to Seller shall consist of: (i) a cash payment equal to [***] ($[***]) reduced by any Closing Liabilities
and Company Transaction Expenses payable at or prior to the Closing (the “Closing Cash Consideration”), and (ii) as, if and when payable pursuant to the terms of this Agreement, (A) the Milestone Payment, and (B) the
Royalty Payments. 
 2.2. Closing; Closing Payments and Deliverables. 

(a) Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at the
offices of Dentons US LLP, 1221 Avenue of the Americas, New York, NY 10020 (or via the electronic exchange of execution versions of the agreements and documents contemplated hereby and the signature pages thereto via facsimile or via email by.pdf),
on the date hereof or at such other place or such other time or on such other date as is agreed to in writing by the Buyer and the Seller. The date of the Closing is referred to herein as the “Closing Date” and the Closing shall be
deemed to occur as of the close of business on the Closing Date. 
 (b) Buyer Closing Payments; Deliverables. At the Closing, the
Buyer shall: 
 (i) pay to Seller, by wire transfer of immediately available funds, an amount equal to the Closing Cash
Consideration (less any applicable withholding Taxes); 

  
 10 

 (ii) repay, or cause to be repaid, on behalf of the Seller or Company, all
Closing Liabilities in the amounts specified in the Schedule 1.1-A, by wire transfer of immediately available funds as directed by the holders of such Closing Liabilities at least three (3) Business
Days prior to the Closing; 
 (iii) pay to the applicable third parties the amount of the Company Transaction Expenses in the
amounts specified on Schedule 1.1-B hereto; and 
 For the avoidance of doubt, in no event shall any party
hereto be entitled to receive interest on any monies to be received pursuant to the terms of this Agreement to the extent such monies are timely paid hereunder or are being validly disputed in accordance with the terms hereof. 

The occurrence of any events and the completion of any actions required by this Section 2.2(b) and in Section 2.2(c) to be made at the Closing shall
be deemed to have taken place simultaneously at the Closing. 
 (c) Seller Closing Deliverables. At the Closing, 

(i) Seller shall deliver to the Buyer (A) all share certificates representing (to the extent Purchased Shares are
represented by certificates) the Purchased Shares held by Seller, together with duly executed endorsements in favor of the Buyer and (B) such other documents as the Buyer may reasonably require; 

(ii) Seller shall deliver to Buyer in forms reasonably satisfactory to the Buyer, copies of all third-party consents set forth
in Schedule 2.2(c)(ii); 
 (iii) Seller shall deliver to the Buyer all Payoff Letters, all in form and substance
reasonably acceptable to the Buyer; 
 (iv) each director and officer of the Company shall tender, as of the Closing, such
director’s resignation as a director and officer; and 
 (v) Seller shall deliver to Buyer a certificate dated as of the
Closing Date, sworn under penalty of perjury in accordance with the requirements of the Treasury Regulations issued pursuant to Section 1445 of the Code, in a form reasonably satisfactory to Buyer, stating that Seller is not a “foreign
person” as defined in Section 1445 of the Code. 
 2.3. Post-Closing Contingent Payments. 

(a) Milestone Payment. 

(i) Subject to the occurrence of the Closing and the set-off rights of Buyer pursuant
to Section 2.3(c), upon the achievement of the Milestone, the Buyer shall make, or cause to be made, to Seller, a one-time cash payment by wire transfer of immediately available funds, in accordance with
Section 2.3(a)(iii), in the amount equal to the Milestone Payment. In no event shall the Buyer be required to make more than one (1) Milestone Payment. The Milestone Payment shall be paid to Seller within ten (10) days of the
achievement of the Milestone. 

  
 11 

 (ii) The Seller acknowledges and agrees that (i) from and after the
Closing, the Buyer and its Affiliates (including the Company) shall be free to operate their business in any manner as the Buyer deems to be in the interest of the Buyer and all of its stockholders and (ii) neither the Buyer nor any of its
Affiliates (including the Company) shall have any duty or obligation with respect to the achievement of the Milestone; provided, however, that from and after the Closing, the Buyer shall, and shall cause the Company to, use its
commercially reasonable efforts to take such action as is reasonably necessary for the achievement of the Milestone (which, for the avoidance of doubt, does not impose any funding obligation on the Buyer, the Company or any member of the Buyer
Rights Chain Group other than as contemplated by this Agreement or the transactions contemplated hereby (including deploying the $[***] with which Parent was capitalized at the Closing). If the Buyer or any other member of the Buyer Rights Chain
Group terminates or abandons all or substantially all development or commercialization activities with respect to the Lead Product, Parent shall send written notice thereof to Seller together with a reasonably detailed explanation of the reasons for
such cessation of activities and how such cessation is consistent with the obligations to use commercially reasonable efforts. 

(iii) The Buyer shall provide written notice to Seller of the achievement of the Milestone no later than twenty
(20) Business Days after the occurrence thereof. The Milestone Payment shall be paid by the Buyer within thirty (30) days following the end of the quarter in which the Milestone was achieved, and the Buyer shall pay, or cause to be paid,
the same to Seller. 
 (b) Royalty Payments. 

(i) Subject to the terms and conditions of this Section 2.3(b) and
Section 2.3(c), Seller shall be entitled to receive an annual royalty payment (each, a “Royalty Payment” and together with the Milestone Payment, the “Contingent Payments”) equal to [***]%
of the Annual Revenue (as defined herein). 
 (ii) Royalty Payments shall become payable on the date that is ninety
(90) days after the first fiscal year in which Annual Revenue is generated, and shall remain payable for ten (10) years thereafter (the “Royalty Term”). 

(iii) For purposes of this Section 2.3(b), “Annual Revenue” means, with respect to a given fiscal year of
the Buyer, the sum of all income of the Buyer and its Controlled (as defined in Section 1.1(r)) Affiliates generated by the Buyer’s and its Controlled (as defined in Section 1.1(r)) Affiliates’ operations during such twelve
(12) month period, including without limitation the cash proceeds actually received by the Buyer from the sale of any Products to unaffiliated third parties, net of Taxes and less discounts and deductions for returned products, or cash payments
received in the form of licensing upfront, milestone or royalty payments, all as determined from the books and records of the Buyer maintained in accordance with GAAP. For the avoidance of doubt, Annual Revenue will not include any proceeds from
transfers or dispositions of any product for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes. For purposes of calculating Annual Revenue, all proceeds shall be in United
States dollars. 

  
 12 

 (iv) During the Royalty Term, Buyer shall deliver to Seller, within sixty
(60) days of the end of each fiscal year of Buyer, a true and accurate report showing all Annual Revenue and sources thereof during the relevant fiscal year in sufficient detail to permit calculation of the Royalty Payment (each, a
“Royalty Report”). 
 (c) Right of Set-Off. Subject to the terms of ARTICLE
VIII hereof (including the limitations on liability set forth therein), the obligation of the Buyer to make any Contingent Payment shall be qualified in its entirety by the right of the Buyer to reduce or retain the amount of such Contingent Payment
by the amount of any Losses for which any Buyer Indemnitee has become entitled to indemnification pursuant to ARTICLE VIII (or, if the amount of such Losses has not been finally determined, then by the amount of Losses reasonably likely to be
indemnifiable hereunder with respect to such indemnification claim as reasonably estimated by the Buyer in good faith and set forth in a timely delivered Claim Notice; provided, that with respect to any such unresolved claim, Buyer’s right of
set off shall only apply for so long as and to the extent that the claims asserted in such Claim Notice remain unresolved hereunder or are determined to be Losses owed to Buyer hereunder, and all other amounts determined not to be Losses owed to
Buyer hereunder shall, promptly after such determination, be distributed by the Buyer to Seller as otherwise provided hereunder), subject to the express limitations on indemnification set forth in ARTICLE VIII. 

(d) Reports; Audits; Record-keeping. 

(i) The Company shall report at least twice annually to the board of directors of the Company with respect to the status of
efforts to achieve the Milestone, and the progress with respect thereto and the then-current plans for progressing toward the achievement thereof. From and after such time as Dr. Jonathan Sporn is no longer an observer (with the right to
receive, at the same time as the board of directors, the information referenced in the preceding sentence) on the board of directors of the Company until such time as the Milestone Payment has been paid by the Buyer (the “Reporting
Period”), the Buyer shall provide Seller, on a semi-annual basis (i.e., every six (6) months), on or about October 1st and April 1st of each year within such period, a written report in reasonable detail regarding the status of efforts to achieve the Milestone, and the progress with respect thereto and the then-current plans for
progressing toward the achievement thereof (each such report, an “Update Report”). Within twenty (20) Business Days after delivery of an Update Report, if Seller requests in writing a meeting with representatives of the Buyer
to discuss such report, the Buyer shall make available for such a meeting those of its representatives as are responsible for the applicable activities set forth in the Update Report (each such person, a “Buyer Milestone
Representative”); Seller may not request more than one (1) meeting with the Buyer Milestone Representatives for any Update Report. Each of the Buyer and Seller shall be solely responsible for bearing its own costs associated with
exercising its rights or performing its obligation under this provision. 

  
 13 

 (ii) Commencing with the first fiscal year in which Annual Revenue occurs,
and until the one year anniversary of the end of the Royalty Term (the “Audit Period”), and thereafter as needed for any audit requested during the Audit Period, the Buyer shall maintain reasonable documentation, consistent with
good business practices and applicable Laws, regarding its Annual Revenue and keep complete and accurate books and records of Annual Revenue to the extent necessary to ascertain properly and to verify the Royalty Payments owed under
Section 2.3(b) and the Royalty Reports delivered pursuant to Section 2.3(b)(iii). 
 (iii) Upon the written request
of Seller, the Buyer shall permit a nationally recognized independent accounting firm (the “Independent Auditor”) selected by Seller and reasonably satisfactory to the Buyer to have access solely in response to a request made during
the Audit Period, upon reasonable prior notice and during normal business hours, but no more than one (1) time during any annual period, to inspect the books and records specified in Section 2.3(d)(i) for the preceding
three (3) years (but only to the extent not previously audited pursuant to a previous audit pursuant to this Section) and only if in response to a request made during the Audit Period for the purpose of determining the accuracy Royalty
Payments. 
 (iv) The Buyer shall notify Seller immediately after the consummation of any license, sublicense, assignment or
transfer of the Company Intellectual Property, or the Chiba License, to any third party. 
 2.4. Withholding Rights. Notwithstanding
any other provision hereof to the contrary, the Buyer and the Company shall be entitled to deduct and withhold from any consideration otherwise payable pursuant to this Agreement to Seller such amounts as it is required to deduct and withhold with
respect to the making of such payment under the Code or any provision of state, local or non-U.S. Tax Laws and shall be entitled to request any reasonably appropriate Tax forms, including an IRS Form W-9 (or the appropriate IRS Form W-8, as applicable), from any recipient of payments hereunder. Before making any such deduction or withholding, the Buyer or the Company, as
applicable, shall use commercially reasonable efforts to provide Seller three (3) days’ advance written notice of the intention to make such deduction or withholding, and Buyer or the Company, as applicable, shall cooperate with any
reasonable request from Seller to obtain reduction of or relief from such deduction or withholding. To the extent that amounts are so withheld and paid over to the applicable Taxing Authority by the Buyer or the Company, such withheld and paid over
amounts shall be treated for all purposes of this Agreement as having been paid to the Seller in respect of which such deduction and withholding was made by the Buyer or the Company. 

  
 14 

 ARTICLE III. 

REPRESENTATIONS AND WARRANTIES OF THE SELLER 

Seller hereby represents and warrants to the Buyer, as of the date hereof, except as set forth on the Disclosure Schedules (subject to
Section 9.10), as follows: 
 3.1. Power and Authorization. Seller has all requisite power, authority and capacity to execute and
deliver this Agreement and the other agreements contemplated hereby to be executed by Seller (in Seller’s capacity as such hereunder) and to perform its obligations hereunder and thereunder. Seller’s execution, delivery and performance of
this Agreement, such other agreements contemplated hereby and the transactions contemplated hereby or thereby have been duly authorized by Seller. This Agreement has been duly executed and delivered by Seller and this Agreement constitutes, and each
such other agreements contemplated hereby upon execution and delivery by Seller and the other parties thereto will constitute, a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as the
enforcement may be affected by bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or other Laws relating to or limiting creditors’ rights generally or by general principles of equity, regardless of whether such
enforceability is considered in a proceeding at law or in equity (the “General Enforceability Exceptions”). 
 3.2. No
Violation. 
 (a) The execution, delivery and performance by Seller of this Agreement and the other agreements contemplated hereby by to
be executed by Seller (in Seller’s capacity as such hereunder) and the consummation of each of the transactions contemplated hereby or thereby will not (i) violate in any material respect any Law or Order to which Seller is subject or
(ii) violate, breach or constitute a default under or give rise to a right of termination, modification, cancellation or acceleration of any right or obligation of Seller under, or result in the creation of a Lien on any of the properties or
assets of Seller pursuant to, any provision of any agreement, contract, note, bond, mortgage, indenture, or lease or other instrument binding upon Seller or any license, franchise, permit or other similar authorization held by Seller, in each such
case, in any manner which would or would reasonably be expected to have an adverse effect on Seller’s ability to consummate the transactions contemplated hereby or to perform its obligations hereunder or which would otherwise result in Losses
of the Company (or, following the Closing, the Buyer). 
 (b) The execution, delivery and performance by Seller of this Agreement and the
consummation of each of the transactions contemplated hereby with respect to Seller do not require Seller to obtain any authorization, consent, permit, approval, exemption or other action from or to provide notice to any Governmental Authority or
other Person except, in each case, for such authorizations, consents, permits, approvals, exemptions, other actions or notices which, if not obtained or provided, would not reasonably be expected to have, individually or in the aggregate, a material
and adverse effect (or with respect to Seller’s obligation to deliver the Purchased Shares pursuant to the terms hereof, any adverse effect) on Seller’s ability to consummate the transactions contemplated hereby (or in such other
agreements contemplated hereby to be executed by Seller in Seller’s capacity as such hereunder) or to perform its obligations hereunder or thereunder. 

  
 15 

 3.3. Ownership of Shares. Seller is the record owner of, and owns legally and
beneficially, all of the Shares in the amounts set forth opposite Seller’s name on Section 4.3(a) of the Disclosure Schedules, free and clear of any and all Liens (other than the rights set forth in this Agreement). At the Closing, Seller
shall transfer to the Buyer good title to Seller’s Shares, free and clear of all Liens and other restrictions on transfer. Seller is not a party to any option, warrant, purchase right, or other Contract or commitment that could require Seller
to sell, transfer or otherwise dispose of any of Seller’s Purchased Shares (other than this Agreement or the other agreements contemplated hereby). Seller does not, with respect to the Company, own any securities, options, warrants, rights,
contracts, pledges, calls, puts, rights to subscribe, conversion rights, rights to purchase, preemptive rights, rights of first refusal, co-sale rights, exchange rights, stock appreciation rights or similar
rights (including rights issued by the Company that are derivative of the price of any capital stock of the Company), phantom stock or other similar agreements or commitments to which Seller is a party or which are binding upon Seller providing for
the voting, issuance, disposition, repurchase, redemptions or acquisition of Seller’s Shares or any rights or interests exercisable therefor. 

3.4. Litigation. There are no actions, suits, arbitrations, proceedings, hearings, orders, investigations, charges, complaints, disputes
or claims at law or in equity, before or by any Governmental Authority (“Actions”) pending or, to Seller’s Knowledge, threatened against or affecting Seller, seeking to restrict the sale by Seller of its Shares claiming any
interest in the proceeds of such sale or which would otherwise adversely affect Seller’s ability to consummate the transactions contemplated by this Agreement. 

3.5. Rights to Company Intellectual Property. Seller does not own or otherwise have any rights with respect to the Company Intellectual
Property. Seller has not at any time, acting in its, his or her individual capacity, transferred or conveyed all or any part of its, his or her direct or indirect ownership or control of, or direct or indirect interest in, any Company Intellectual
Property to any third party (other than the Company). Seller has transferred to the Company to the fullest extent permissible under applicable Laws, without retaining any rights to receive royalties or any other compensation, all Company
Intellectual Property developed, created, or invented by Seller while engaged by or affiliated with the Company. 
 ARTICLE IV. 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

Seller hereby represents and warrants to the Buyer, as of the date hereof, except as set forth on the Disclosure Schedules (subject to
Section 9.10), as follows: 
 4.1. Organization and Power; Investments. The Company is a corporation, duly organized and validly
existing under the laws of Delaware. The Company is qualified to do business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect. The Company has all requisite corporate power and
corporate authority to carry on its business as currently conducted. The Company does not own or control (directly or indirectly) any shares, partnership interest, joint venture interest, equity participation or other security or interest in any
other Person, other than in a Subsidiary. The Seller has made available to the Buyer correct and complete copies of the articles of association (or other comparable organizational and governing documents) of the Company and all amendments thereto as
in effect on the date hereof. 

  
 16 

 4.2. [Intentionally Omitted]. 

4.3. Capitalization; Subsidiaries. 

(a) The authorized capital stock of the Company consists of [***] shares of common stock, no par value per share, of which [***] shares are
issued and outstanding (prior to giving effect to the Rollover). All of the issued and outstanding shares of the Company’s capital stock have been duly authorized, are validly issued, fully paid, and nonassessable and are not subject to, nor
were they issued in violation of, any preemptive rights, rights of first refusal or similar rights or applicable securities laws, and are owned of record and beneficially by the Seller free and clear of all Liens. Other than Seller, and Kranzler,
who owns [***] shares of common stock of the Company (prior to giving effect to the Rollover), there are no other holders of Shares. 
 (b)
Except as disclosed in Section 4.3(a) and Section 4.3(c) of the Disclosure Schedules, and except for this Agreement and the Rollover Agreement, there are no outstanding or authorized securities, options, warrants, rights, contracts,
pledges, calls, puts, rights to subscribe, conversion rights, rights to purchase, preemptive rights, co-sale rights, exchange rights, stock appreciation rights or similar rights (including rights issued by the
Company that are derivative of the price of any capital stock of the Company), phantom stock or other agreements or commitments to which the Company is a party or which are binding upon the Company providing for the voting, issuance, disposition,
repurchase, redemptions or acquisition of the Company’s capital stock or other equity or any rights or interests exercisable therefor. The Company is not committed to declare, pay or set aside for payment any dividend or other distribution
(whether in cash, stock, property or otherwise) in respect of any of the capital stock of the Company or any other securities of the Company. The Company is not obligated or required to make any investment (including in the form of a loan or capital
contribution) in any Person. 
 (c) Section 4.3(c) of the Disclosure Schedules sets forth a true and complete list of all
stockholders’ agreements, voting agreements, voting trusts, proxies or other Contracts to which the Company is a party and that relate to any class of capital stock of the Company, and the Company has delivered to the Buyer correct and complete
copies of all such Contracts. There are no bonds, debentures, notes or other Indebtedness of the Company having the right to vote (or convertible into or exchangeable for securities having the right to vote) on any matters on which holders of the
capital stock of the Company are entitled to vote. 
 (d) Following the consummation of each of the transactions contemplated by this
Agreement, neither the Buyer nor the Company will have any obligation to make any payment to any Person with respect to the ownership of any capital stock of the Company, other than payment of the amounts as required by this Agreement or the other
agreements contemplated hereby, including the Rollover Agreement. 

  
 17 

 (e) Section 4.3(e) of the Disclosure Schedule lists each of the Subsidiaries of
the Company as of the date hereof and indicates for each such Subsidiary as of such date (i) the percentage and type of equity securities owned or controlled, directly or indirectly, by the Company, and (ii) the jurisdiction of
incorporation or organization. No Subsidiary of the Company has or is bound by any outstanding subscriptions, options, warrants, calls, commitments, rights agreements, or agreements of any character calling for it to issue, deliver, or sell, or
cause to be issued, delivered, or sold any of its equity securities or any securities convertible into, exchangeable for, or representing the right to subscribe for, purchase or otherwise receive any such equity security or obligating such
Subsidiary of the Company to grant, extend or enter into any such subscriptions, options, warrants, calls, commitments, rights agreements, or other similar agreements. There are no outstanding contractual obligations of any Subsidiary of the Company
to repurchase, redeem, or otherwise acquire any of its capital stock or other equity interests. All of the shares of capital stock of each Subsidiary of the Company (A) have been duly authorized and are validly issued, fully paid (to the extent
required under the applicable governing documents) and nonassessable, and (B) are owned by the Company free and clear of any Liens, or agreement with respect thereto. 

4.4. Intentionally Omitted. 

(a) The execution, delivery and performance by the Seller of this Agreement and the other agreements contemplated hereby to which Seller is
party and the consummation of each of the transactions contemplated hereby or thereby will not (i) violate or conflict with any provision of the organizational and governing documents of the Company as in effect on the date hereof,
(ii) assuming satisfaction of the requirements set forth in Section 4.4(b), violate in any material respect any Law or Order to which the Company is subject or (iii) violate, breach or constitute a default under or give rise to a
right of termination, modification, cancellation or acceleration of any right or obligation of the Company under, or result in the creation of a Lien or encumbrance on any of the properties or assets of the Company or require any notice or consent
pursuant to, any provision of any Contract binding upon the Company or any Permit or other similar authorization held by the Company or otherwise cause such agreement to cease to be legal, valid, binding and enforceable and in full force and effect
following the Closing. 
 (b) The execution, delivery and performance by the Seller of this Agreement and the other agreements contemplated
hereby to which the Seller is party and the consummation of each of the transactions contemplated hereby or thereby will not require the Company to obtain any authorization, consent, approval, exemption or other action from or to provide notice to
any Governmental Authority or any other Person under the provisions of any applicable Law. 
 4.5. Financials; Bank Accounts; Accounts
Receivable. 
 (a) Seller has made available to Buyer an unaudited statement of assets and liabilities of Company (the “Latest
Balance Sheet”) as of November 2, 2018 (the “Latest Balance Sheet Date”). 
 (b) Section 4.5(a) of the Disclosure
Schedules sets forth a true and complete list of the bank accounts of the Company and the balance of each such account as of the date immediately preceding the date of this Agreement. 

  
 18 

 (c) All of the accounts receivable of the Company (i) represent actual indebtedness
incurred by the applicable account debtors and (ii) have arisen from bona fide transactions in the ordinary course of business of the Company. 

4.6. Absence of Certain Developments. Since the date of the Latest Balance Sheet until the date hereof (but excluding the effect of any
of the transactions specifically contemplated hereby), the Company has conducted its business in the usual and ordinary course consistent with past practice, and during such period the Company has not: 

(a) suffered any Material Adverse Effect or any theft, damage, destruction or casualty loss in excess of $10,000, individually or in the
aggregate, to its assets (whether owned, leased or used), whether or not covered by insurance or suffered any substantial destruction of its books and records; 

(b) redeemed or repurchased, directly or indirectly, any shares of capital stock or other equity security or declared, set aside or paid any
dividends or made any other distributions (whether in cash or in kind) with respect to any shares of its capital stock or other equity security; 

(c) issued, sold or transferred any equity securities, any securities convertible, exchangeable or exercisable into shares of its capital stock
or other equity securities, or warrants, options or other rights to acquire shares of its capital stock or other of its equity securities; 

(d) incurred or become subject to any Indebtedness, except Indebtedness incurred in the ordinary course of business consistent with past
practice and not exceeding $10,000, individually or in the aggregate; 
 (e) forgiven or canceled any debts or claims, waived any rights or
discharged or satisfied any Lien, or paid any Indebtedness, other than current liabilities in the ordinary course of business; 
 (f)
subjected any portion of its properties or assets to any Lien; 
 (g) sold, leased, assigned or transferred (including, without limitation,
transfers to the Seller) a material portion of its assets, except for sales of inventory and sales or trades of obsolete equipment in the ordinary course of business consistent with past practice; 

(h) sold, assigned, licensed or transferred any proprietary rights owned by, issued to or licensed to it or disclosed any confidential
information (other than pursuant to agreements requiring the recipient to maintain the confidentiality of such confidential information) or solicited any confidential information of any third party in violation of any obligation of confidentiality;

 (i) materially changed its financial or tax accounting principles or methods, credit policies or practices, or any other business
practice; 
 (j) made or granted any bonus or any wage, salary or compensation increase to any director, officer, employee or sales
representative, group of employees or consultant or made or granted any increase in any employee benefit plan (if any) or arrangement, or amended or terminated any existing employee benefit plan or arrangement or adopted any new employee benefit
plan or arrangement or as required by applicable Law; 

  
 19 

 (k) made any other change in employment terms for any of its directors, officers and
employees, including any change to termination and severance pay payable or to become payable to such persons; 
 (l) conducted its cash
management customs and practices other than in the ordinary course of business consistent with past practice; 
 (m) made any loans or
advances to, or guarantees for the benefit of (except endorsements in the ordinary course of business or advances to employees for travel expenses, in each case consistent with past practice) any Person; 

(n) waived any significant rights relating to the business of the Company; 

(o) changed (or authorized any change) in its articles of incorporation or by-laws; 

(p) committed, either orally or in writing, to do any of the foregoing; or 

(q) (i) made any a material election relating to Taxes or revoked any election relating to material Taxes other than in the ordinary
course of business; (ii) settled or compromised any Action, audit or controversy relating to material Taxes; (iii) changed any methods of reporting income or deductions for any income, franchise or other material Tax purposes or any annual
Tax accounting period; (iv) filed any amended Tax Returns; (v) entered into any Tax allocation agreement, Tax sharing agreement or closing agreement relating to any material Tax (excluding agreements entered into in the ordinary course of
business the primary purpose of which does not relate to Taxes); or (vi) surrendered any right to claim a Tax refund. 
 4.7. Title
to Properties. 
 (a) Owned Properties. The Company does not own any real property. 

(b) Leased Properties. Section 4.7(b) of the Disclosure Schedule sets forth a true and complete list of all of the leases (the
“Leases”) and each leased parcel of real property in which the Company has a leasehold interest (the “Leased Real Property”). Seller has delivered to the Buyer true, correct, complete and accurate copies of each of
the Leases described in Section 4.7(b) of the Disclosure Schedule. With respect to each Lease listed on Section 4.7(b) of the Disclosure Schedule: (i) the Lease is legal, valid, binding,
enforceable and in full force and effect and the Company holds a valid leasehold interest under the Lease; and (ii) neither the Company nor, to the Knowledge of the Seller, any other party to the Lease is in breach or default, and no event
involving the Company or, to the Knowledge of the Seller, any other party to the Lease, has occurred which, with notice or lapse of time, would constitute such a breach or default or permit termination, modification or acceleration under the Lease.

  
 20 

 (c) Current Use and Condition and Operation of Improvements. The Company’s
current and prior use of the Leased Real Property does not violate in any material respect any instrument of record or agreement affecting such Leased Real Property and is and was in material compliance with, includes all rights necessary to assure
material compliance with, and all buildings, structures, other improvements and fixtures on the Leased Real Property and the operations therein conducted by the Company conform in all material respects to, all applicable health, fire, water,
environmental, safety, zoning, building, use or similar rules and regulations. To the Knowledge of the Seller, there is not currently nor has there ever been any violation by the Company of any covenant, condition, restriction, easement, agreement
or order of any governmental authority having jurisdiction over any of the Leased Real Property that affects such real property or the use or occupancy thereof by the Company; and the prior or current use by the Company of the Leased Real Property
is not dependent on a nonconforming use or other approval from a governmental authority, the absence of which would significantly limit the use of any of the properties or assets in the operation of the business of the Company. The Company has all
licenses, certificates of occupancy, permits and authorizations required to utilize the Leased Real Property as currently utilized by the Company. 

4.8. Title to Assets; Condition of Assets. Except as set forth on Section 4.8 of the Disclosure Schedule, and except with respect
to Intellectual Property or other intangible assets, the Company has good and marketable title to, or a valid leasehold interest in, all of the assets used in its business, including, without limitation, the properties and assets located on its
premises or shown on the Latest Balance Sheet or acquired thereafter, free and clear of all Liens. Except as described on Section 4.8 of the Disclosure Schedule, the Company’s buildings, equipment and other tangible assets currently in use
in the Company’s operation are in good operating condition and are adequate for the conduct of the business of the Company as currently conducted. The Company owns or leases all buildings, machinery, equipment, and other tangible assets
necessary for the conduct of its business as presently conducted. 
 4.9. Contracts and Commitments. Section 4.9 of the
Disclosure Schedules contains a true and complete list of the following agreements, contracts, notes, bonds, mortgages, indentures, leases or other instruments, licenses, franchises, commitments, guarantees, purchase orders, or other binding
commitments, obligations or undertakings, including all amendments, supplements or modifications thereto (each, whether written or oral, a “Contract”) to which the Company is a party or by which the Company or its assets are bound
and under which the Company has any remaining rights or obligations (each, a “Material Contract”): 
 (i)
any Contract (or group of related Contracts) that provides for the purchase of goods or services (excluding employment agreements), including supply agreements and license agreements pursuant to which the aggregate of payments due to or from the
Company is equal to or exceeds $5,000 on an annual basis or is reasonably likely to equal or exceed $5,000 in the aggregate over the remaining term of such Contract; 

(ii) any Contract concerning the establishment or operation of a partnership, joint venture, limited liability company or a
similar arrangement; 
 (iii) any Contract containing covenants of the Company or any of its controlled Affiliates not to (or
otherwise restricting or limiting or purporting to restrict or limit the ability of the Company or any of its controlled Affiliates to) compete in any line of business or geographic or therapeutic area, including any covenant not to compete with
respect to the manufacture, marketing, distribution or sale of any Product Candidate; 

  
 21 

 (iv) any Contract (or group of related Contracts) under which the Company
has created, incurred, assumed or guaranteed (or may, pursuant to the terms thereof, create, incur, assume or guarantee) Indebtedness in excess of $5,000; 

(v) any Contract with any officer, manager, employee, director, consultant or independent contractor that requires (or could
require pursuant to the terms thereof) the Company to pay compensatory amounts (including severance payments and tax gross- up payments) to such Person excluding accrued wages or other benefits required to be paid by Law; 

(vi) any collective bargaining agreements or employee benefit plans; 

(vii) any Contract with Seller, Kranzler, a Related Party or a Related Company; 

(viii) any Contract (or group of related Contracts) for capital expenditures or the acquisition or construction of fixed assets
in excess of 5,000; 
 (ix) any Contract (or group of related Contracts) for the lease of personal property from or to third
parties for annual payments in excess of $5,000; 
 (x) any Contract, other than currently available off-the-shelf software programs (A) granting any rights to or placing any restrictions upon the Company’s ability to use or develop any Company Intellectual
Property, (B) to which the Company is a party and pursuant to which the Company is authorized to use any Intellectual Property of any other Person or (C) imposing an obligation on any Person to convey to the Company an interest in any
Intellectual Property; 
 (xi) any Contract for the disposition of any material assets of the Company in excess of $5,000;

 (xii) any Contract for the acquisition of any material assets or any business or any corporation, partnership, joint
venture, limited liability company, association or other business organization or division thereof, except purchases of Inventory in the ordinary course of business consistent with past practice; 

(xiii) any Contract (other than purchase orders or similar arrangements with no continuing obligations lasting beyond thirty
(30) days) under which the Company covenants and agrees to purchase all or substantially all its requirements for a specific product or service from any Person, or to supply all or substantially all of any Person’s requirements (or provide
for monetary payment in lieu of supplying such requirements) for a specific product or service, or any Contract (or group of related Contracts) under which the Company has minimum purchase or sale obligations of $5,000, or more over the remaining
term of such Contract (or group of related Contracts); 

  
 22 

 (xiv) any Contract granting any Person an option, a preferential or other
right to purchase or license the Company’s assets or properties; 
 (xv) any Contract providing for the indemnification
of any Person with respect to liabilities relating to any current or former business of the Company (other than customary and ordinary course indemnification provisions contained in customer or supplier contracts entered into in the ordinary course
of business); 
 (xvi) any engagement letter or similar Contract with any broker, finder or investment banker in effect as of
the date hereof; 
 (xvii) any Contract providing for the settlement of any Action or threatened Action; 

(xviii) powers of attorney and any other similar authorization documents executed on behalf of the Company; 

(xix) any Contract not otherwise disclosed pursuant to this Section 4.9 that if terminated or not renewed at expiration
would reasonably be expected to have a Material Adverse Effect; 
 (xx) any Contract with a Provider; 

(xxi) any Contract involving a grant or payment of monies to or from, or a binding commitment to a Governmental Authority; 

(xxii) any Contract with an official, employee or representative of any Governmental Authority (acting in their capacity as
such), or any entity, to the Seller’s Knowledge, owned or controlled by such Person; 
 (xxiii) any Contract relating to
any of the Company’s Permits; 
 (xxiv) any Contract that imposes exportation obligations on the Company; and 

(xxv) any Contract not otherwise disclosed pursuant to this Section 4.9 which is not entered into in the ordinary course
of business and is material to the Company’s business, results of operations or financial position or its ability to perform the transactions contemplated by this Agreement. 

(b) No Breach, Etc. (i) The Company has not materially breached any Material Contract, and, to the Seller’s Knowledge, no
Material Contract has been materially breached in any respect or cancelled by any other party or parties thereto, (ii) neither the Company nor the Seller is in receipt of any written claim of default under any such Contract, (iii) to the
Seller’s Knowledge, no event has occurred that with the passage of time or the giving of notice or 

  
 23 

 
both would result in a material breach or material default under any such Contract and (iv) as of the date of this Agreement, to the Seller’s Knowledge, no party to such Contract is
attempting to renegotiate any material terms of such Contract. Each Material Contract is valid, binding, in full force and effect, and enforceable (subject to the General Enforceability Exceptions) against the Company and, to the Seller’s
Knowledge, against the other party or parties thereto. With respect to each Material Contract, the Seller has made available to the Buyer a correct and complete copy of each written Contract (as amended to date) and a written summary setting forth
the terms and conditions of each oral Contract. 
 4.10. Intellectual Property. 

(a) Except as set forth in Section 4.10(a) of the Disclosure Schedule, the Company owns the entire right, title and interest in and to,
free and clear of any Liens, the Company Intellectual Property and, to the extent that there are any limitations or restrictions on the Company’s ownership of the Company Intellectual Property, such limitations or restrictions are set forth and
explained in Section 4.10(a) of the Disclosure Schedule. As of immediately following the Closing, the Company will continue to own such entire right, title and interest in and to, and such right to enjoy and exploit for its benefit, the Company
Intellectual Property. Title in all Company Intellectual Property is in the name of the Company. No Person has any right or claim in any of the Company Intellectual Property as a result of that Person having previously employed or engaged as a
consultant anyone involved in the development, testing and manufacture of Products. 
 (b) Except as otherwise disclosed on
Section 4.10(b) of Disclosure Schedule there are no outstanding options, licenses, or agreements of any kind pursuant to which either the Company or the Seller has granted or has received a grant of rights with respect
to, the Company Intellectual Property, nor is the Company, the Seller or any Subsidiary of the Company bound by or a party to any options to grant or receive a license or to assign rights to, or any licenses, or agreements of any kind with respect
to the transfer of any Company Intellectual Property. Neither the Company nor any Subsidiary of the Company has received any communications alleging that the Company or any Subsidiary of the Company has infringed or misappropriated or, by conducting
the Current Company Business, would infringe or misappropriate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, or other proprietary rights of any other person or entity. 

(c) There is not now and, to the Seller’s Knowledge has not been at any time in the past a pending or threatened Action by any Person
contesting the Company’s ownership or other rights in or contesting the validity of any Company Intellectual Property and, to the Knowledge of the Seller, there is no basis for any such claim, suit or proceeding, nor, to the Knowledge of the
Seller, are any of the issued Patents within the Company Intellectual Property invalid or unenforceable. There is not now and, to the Seller’s Knowledge, has not been at any time in the past any pending or threatened claim, suit or proceeding
by another that alleges that the operation, manufacturing, testing, marketing, offer for sale, sale, importation or use of any Product Candidate or Product, infringes or misappropriates or otherwise violates any intellectual property of any Person
or will infringe a patent issuing from a pending patent application if and when such patent application issues as a patent, and, except with respect to any issues that there may be with respect to those Patents listed in
Section 4.10(c) of the Disclosure Schedule, to the Knowledge of 

  
 24 

 
the Seller, the operation, manufacture, testing, marketing, offer for sale, sale or use of any of the Product Candidates or Products of the Company, do not infringe, misappropriate, or otherwise
violate any intellectual property rights of any third party nor will infringe a patent issuing from a pending patent application if and when such a patent application issues as a patent. Except as disclosed in
Section 4.10(c) of the Disclosure Schedules, the Company is not party to any contract, agreement, undertaking or other obligation that would impede or prevent the continued and unfettered use or enjoyment by the Company of
the Company Intellectual Property. 
 (d) Except as disclosed in Section 4.10(d) of the Disclosure Schedule, the
Company has valid and enforceable agreements that require an assignment to the Company of all right, title, and interest in and to inventions and technical know-how, whether patentable or not, relating to the
Company Intellectual Property, with all consultants, employees, and other Persons previously or presently involved in the development, testing and manufacture of the products and methods of the Company. 

(e) The Company, or to the Seller’s Knowledge, its licensor, has filed all applications and documents necessary to ensure the continued
prosecution and/or issuance of and paid all fees necessary to assure the continued maintenance and/or existence of all patents, patent applications, and trademark applications forming part of the Company Intellectual Property. With respect to
inventions that have not yet been incorporated into patent applications or provisional applications, the Company has not disclosed such inventions without restriction on confidentiality and has not offered for sale products embodying the inventions,
nor taken any other action that jeopardizes the Company’s right to properly and timely file patent applications to cover such inventions such that the Company can obtain valid patents. 

(f) Neither the Company nor any stockholder of the Company or the Company’s Subsidiaries has asserted rights in any of the Company
Intellectual Property against any Person in a formal legal proceeding or in any cease and desist letter or other notice, including in the nature of offering a license or covenant not to sue. 

(g) Except as disclosed in Section 4.10(g) of the Disclosure Schedule, the Company has taken all reasonable steps to
protect and safeguard the secrecy of confidential information and Trade Secrets used in the business of the Company. All employees, consultants, agents and those Persons previously or presently involved and those Persons likely to be involved prior
to Closing in the development and manufacture of products on behalf of the Company, and any other Persons having any knowledge of or exposure to the development and manufacture of such products, have agreed in writing to maintain in confidence any
confidential information or trade secrets relating to such development and manufacture. Notwithstanding the foregoing, there are certain instances in which certain information is not subject to confidentiality by certain third parties or written
confidentiality agreements were not obtained. 
 (h) Except as disclosed in Section 4.10(h) of the Disclosure
Schedule, the Company has not entered into any agreement requiring the Company to indemnify any Person against infringement of any intellectual property owned by others, nor has the Company entered into any agreement requiring the Company to grant
any Person the right to bring infringement actions or otherwise enforce rights with respect to the Company Intellectual Property, nor has the Company granted a license or covenant not to sue on any of the Company Intellectual Property.

  
 25 

 
Except as disclosed in Section 4.10(h) of the Disclosure Schedule, the Company has not been granted any indemnity against infringement by the Company of any intellectual
property owned by others, nor has the Company been granted any licenses or covenants not to sue by any third party relating to any intellectual property owned by others. 

(i) Except as disclosed in Section 4.10(i) of the Disclosure Schedule, no stockholder, Affiliate, officer, director
or employee of the Company, or consulting or investigating physician owns, directly or indirectly, in whole or in part, any of the Company Intellectual Property. Except as disclosed in Section 4.10(i) of the Disclosure
Schedule, no stockholder, Affiliate, officer, director or employee of the Company owns, directly or indirectly, in whole or in part, any invention, technical know-how, including tooling and processing
knowledge for both manufacturing and testing, patent, proprietary right, trademark, service mark, trade name, brand name or copyright, or application therefor (i) the rights to which are presently or would be required to make, use (including
surgical methods), offer for sale, sell, import, market or distribute the Company’s Product Candidates; (ii) that the Company is presently using, developing or testing; (iii) the use of which is necessary for the conduct of the
Current Company Business. 
 (j) The Company possesses under appropriately obtained licenses or authorizations the right to use all software
programs that the Company presently uses in conducting the Current Company Business. 
 (k) The Seller has disclosed to Buyer all studies,
searches and investigations conducted on behalf of the Company with respect to the right to use any products of the Company, whether proposed products or actual products, and the Seller has provided Buyer with all materials relating to such studies,
searches and investigations. 
 4.11. Permits. Except as set forth in Section 4.11 of the Disclosure Schedules, the Company owns
or possesses all right, title and interest in and to all of the Permits that are necessary pursuant to any Laws (or any Governmental Authority) to own and operate the business of the Company as presently conducted, and, to the Seller’s
Knowledge, the Company owns or possesses all right, title and interest in and to all other Permits necessary to own and operate the business of the Company as presently conducted. Section 4.11 of the Disclosure Schedules contains a true and
complete list of all such Permits. Each of such Permits is valid and subsisting in full force and effect. The Company is in compliance with the material terms and conditions of such Permits and the Company has not received any written notices that
the Company is in violation of any of the terms or conditions of such Permits. To the Knowledge of the Seller, no event has occurred or condition or state of facts exists that would constitute a breach or default or would cause revocation or
termination of any such Permit. To the Knowledge of the Seller, no Governmental Authority is considering limiting, suspending or revoking such Permits. 

4.12. Litigation; Proceedings. There are no Actions pending or, to the Knowledge of the Seller, threatened against the Company, any of
its assets or the business of the Company. There are no outstanding or unsatisfied orders, judgments, writs, stipulations, settlements, awards, injunctions, decrees, arbitration awards or findings to which the Company is a party. There were no
disputes or Actions that have been settled or resolved by litigation or arbitration since the date of the Company’s incorporation. 

  
 26 

 4.13. Compliance with Laws. 

(a) The Company is in compliance in all material respects with all applicable Laws relating to the Company or its business (as currently
conducted) or properties currently held. No written notice has been received by the Company from any Governmental Authority or any Person alleging a violation of or liability under any applicable Law, in each case, which has actually resulted in any
such liability or which remains unresolved as of the date hereof. To the Company’s Knowledge, no event has occurred or circumstance exists that would reasonably be expected to result in a material violation by the Company of any applicable Law.

 (b) Neither the Company nor, to the Seller’s Knowledge, its Affiliates or any directors, officers, managers, employees,
representatives, joint ventures, consultants, agents, Providers, or any other Person acting on behalf of the Company or any of its Affiliates (i) has violated or is in violation of any Anti-Bribery Laws, (ii) has made, offered to make,
promised to make, agreed to make, facilitated or authorized the payment or giving of, directly or indirectly, any bribe, rebate, discount (other than lawful rebates and discounts in the ordinary course of business), payoff, influence payment,
kickback, contribution, donation or other unlawful payment or gift of money or anything of value in each case prohibited under any applicable Anti-Bribery Law concerning such payments or gifts in any jurisdiction (any such payment, a
“Prohibited Payment”), (iii) has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties or made any false, incomplete or misleading entries on any books or records for any
purpose in any case, (iv) has used, or is using, directly or indirectly, any corporate funds for any Prohibited Payments, (v) has offered, paid, given, promised to pay or give, or authorized the payment or giving of anything of value,
regardless of form or amount, to any (A) government official or employee, (B) employee of a government-owned or government- controlled enterprise, (C) political party, political official or candidate for political office,
(D) officer or employee of a public international organization, (E) physician, nurse, medical researcher, hospital employee, public university employee or other healthcare professional or administrator or (F) other Person acting in an
official capacity for or on behalf of any such government, enterprise, party, organization, hospital or university, in each case under this clause “(v)”, for the purpose of securing an improper advantage for the Company in violation of any
Anti-Bribery Laws, (vi) is or has been under administrative, civil or criminal investigation, indictment, suspension, debarment or audit by any party in connection with alleged or possible violations of any Anti-Bribery Law or (vii) has
received written notice from, or made a voluntary disclosure to, any Governmental Authority with regard to any Prohibited Payment or any alleged or possible violations of any Anti-Bribery Law. With respect to this Section 4.13(b) and the
Company’s Providers, the reasonable inquiry contemplated by the definition of “Knowledge” shall mean a reasonable inquiry of the relevant Company employees and other personnel. 

4.14. Environmental Matters. Except as could not reasonably be expected to have a Material Adverse Effect (a) the Company is and
has been in compliance with all Environmental Laws; (b) there has been no release or, to the Seller’s Knowledge, threatened release of Hazardous Materials, on, upon, into or from any site currently or heretofore owned, leased or otherwise
used by the Company; (c) there have been no Hazardous Materials generated by the Company that have been disposed of or come to rest at any site that has been included in any published U.S. federal, state or local “superfund” site
list or any other similar list of hazardous or toxic waste sites published by any governmental authority in the United States; and (d) there are no underground 

  
 27 

 
storage tanks located on, no polychlorinated biphenyls (“PCBs”) or PCB-containing equipment used or stored on, and no hazardous waste as
defined by the Resource Conservation and Recovery Act, as amended, stored on, any site owned or operated by the Company, except for the storage of hazardous waste in compliance with Environmental Laws. The Company has made available to the Buyer
true and complete copies of all material environmental records, reports, notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies and environmental studies or assessments. 

4.15. Employee Matters; ERISA. 

(a) As of the date hereof, the Company employs zero full-time employees and zero part-time employees and engages nine consultants or
independent contractors. Section 4.15(a) the Disclosure Schedule sets forth a detailed description of all compensation, including, as applicable, consulting fee(s) for each consultant and independent contractor and salary, bonus, severance
obligations and deferred compensation paid or payable for each officer, employee, of the Company (if applicable) as of the date hereof. 

(b) To the Seller’s Knowledge, none of its employees (if any) is obligated under any contract (including licenses, covenants or
commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the Company or that would
conflict with the Company’s business. Neither the execution or delivery of the this Agreement, nor the carrying on of the Company’s business by the employees (if any) of the Company, nor the conduct of the Company’s business as now
conducted and as presently proposed to be conducted, will, to the Seller’s Knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under
which any such employee is now obligated. 
 (c) The Company is not delinquent in payments to any of its employees (if any), consultants, or
independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors.
The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification and collective
bargaining. The Company is not obligated to withhold and pay to the appropriate governmental entity amounts required to be withheld from employees. The Company is not liable for any arrears of wages, taxes, penalties or other sums. 

(d) To the Seller’s Knowledge, no employee intends to terminate employment with the Company or is otherwise likely to become unavailable
to continue as an employee, nor does the Company have a present intention to terminate the employment of any of the foregoing. The employment of each employee (if any) of the Company is terminable at the will of the Company. Except as set forth in
Section 4.15(d) of the Disclosure Schedule or as required by law, upon termination of the employment of any such employees, no severance or other payments will become due. Except as set forth in Section 4.15(d) of the Disclosure
Schedule, the Company has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination of employment services. 

  
 28 

 (e) The Company has not made any representations regarding equity incentives to any officer,
employee, director or consultant that are inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s board of directors. 

(f) Each former employee (if any) whose employment was terminated by the Company has entered into an agreement with the Company providing for
the full release of any claims against the Company or any related party arising out of such employment. 
 (g) The Company does not maintain,
establish or sponsor, participate in or contribute to, any employee benefit plan which is subject to ERISA. 
 (h) The Company is not bound
by or subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Knowledge of the Seller,
has sought to represent any of the employees, representatives or agents of the Company. There is no strike or other labor dispute involving the Company pending, or to the Seller’s Knowledge, threatened, nor is the Company aware of any labor
organization activity involving its employees. 
 (i) To the Knowledge of the Seller, none of the employees (if any) or directors of the
Company has been (a) subject to voluntary or involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his business or property;
(b) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (c) subject to any order, judgment or decree (not subsequently reversed, suspended, or
vacated) of any court of competent jurisdiction permanently or temporarily enjoining him from engaging, or otherwise imposing limits or conditions on his engagement in any securities, investment advisory, banking, insurance, or other type of
business or acting as an officer or director of a public company; or (d) found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any
federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated. 

(j) Employee Agreements. Each current and former employee, consultant and officer of the Company has executed an agreement with the Company
regarding confidentiality and proprietary information and invention assignment substantially in the form or forms delivered to the counsel for the Buyer (the “Confidential Information Agreements”). No current or former employee,
consultant or officer has excluded works or inventions from his or her assignment of inventions pursuant to such Confidential Information Agreement. 

4.16. Absence of Undisclosed Liabilities. The Company does not have any Liabilities of the nature that would be required to be listed in
the “liabilities” column of a balance sheet in accordance with U.S. generally accepted accounting principles, other than (a) liabilities reflected in the Latest Balance Sheet, (b) liabilities incurred after the Latest
Balance Sheet Date in the ordinary course of business not exceeding $10,000 in the aggregate, and (c) performance obligations under the terms of Material Contracts in effect on the date hereof. Notwithstanding the foregoing, this
Section 4.16 does not address, and shall not be deemed to be a representation or warranty with respect to, any Liabilities of the Company of the nature addressed by other representations and warranties set forth in this ARTICLE IV. 

  
 29 

 4.17. Tax Matters. The Company has filed (or cause to be filed) all income and other
material Tax Returns required to be filed by or with respect to the Company and each Subsidiary of the Company prior to the date hereof as required by Law. All such Tax Returns are true, correct and complete in all material respects. The Company and
each Subsidiary of the Company has timely paid all income Tax and all other material Taxes whether or not shown as due on such Tax Returns. All liabilities for Taxes of the Company through the date of the Latest Balance Sheet have been duly
accounted for in the Latest Balance Sheet. The Company has never received any written claim from a Taxing Authority of any Tax deficiency proposed or assessed against the Company or any Subsidiary of the Company and the Company and each Subsidiary
of the Company has not executed any waiver of any statute of limitations on the assessment or collection of any Tax. There is no claim, audit, suit, proceeding or investigation now pending, or to the Seller’s Knowledge, threatened against or
with respect to, the Company in respect of any Tax. The Company has withheld or collected from each payment made to each of its employees, consultants, contractors, suppliers, creditors and stockholders, all material Taxes required to be withheld or
collected therefrom, and has paid the same to the proper Taxing Authority. There is no Tax sharing agreement, Tax allocation agreement, Tax indemnity obligation, or similar agreement, arrangement, understanding, or practice, oral or written, with
respect to Taxes that will require any payment by the Company (excluding agreements entered into in the ordinary course of business the primary purpose of which does not relate to Taxes). Neither the Company or any Subsidiary of the Company has
received any written claim from a Taxing Authority in a jurisdiction where the Company or such Subsidiary does not file Tax Returns that it is or may be subject to Tax by that jurisdiction. Neither the Company nor its Subsidiaries has granted any
power of attorney which is currently in force with respect to any material Taxes or material Tax Returns. None of the Company or any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in
a transaction that was intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code. The Company is not, and has not been during the applicable period specified in Section 897(c)(1)(A)(ii) of the
Code, a “United States real property holding corporation” within the meaning of Section 897(c)(2) of the Code. None of the Company nor any Subsidiary of the Company (i) has any liability for the Taxes of any Person (other than
the Company and its Subsidiaries) by reason of Treasury Regulations Section 1.1502-6 (or any analogous provision of state, local or non-U.S. Law), contract
(excluding contracts entered into in the ordinary course of business the primary purpose of which does not relate to Taxes), assumption, transferee or successor liability, or otherwise by operation of Law, (ii) has ever been a member of an
affiliated, consolidated, combined or unitary group filing for federal or state income Tax purposes (other than a group the common parent of which is the Company), and (iii) has entered into any transaction identified as a “listed
transaction” within the meaning of Treasury Regulation Section 1.6011-4(b). There are no Tax liens upon any property or assets of any the Company or any Subsidiary of the Company other than Permitted
Liens. Neither the Company, nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing
Date which taxable income was realized (and reflects economic income arising) prior to the Closing Date as a result of any: (i) change in method of accounting for a taxable period ending on or prior to the Closing Date, including by reason of
the application of Section 481 of the Code (or any analogous provision of state, local or non-U.S. Law), made prior 

  
 30 

 
to the Closing; (ii) “closing agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or
non-U.S. Law) executed prior to the Closing; (iii) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of Code (or any corresponding or similar
provision of state, local, or non-U.S. income Tax Law) with respect to any transaction entered into prior to the Closing; (iv) installment sale or open transaction disposition made on or prior to the
Closing Date; (v) prepaid amount received outside the ordinary course of business on or prior to the Closing Date; (vi) election under Section 108(i) of the Code; or (viii) application under Section 965 of the Code
(including any election thereunder). Neither the Company nor any Subsidiary of the Company (i) has, or has ever had, a permanent establishment in any country other than the country in which it is organized and resident, (ii) has engaged in
a trade or business in any country other than the country in which it is organized and resident that subjected it to Tax in such other country, and (iii) is, or has ever been, subject to Tax in a jurisdiction outside the country in which it is
organized and resident. No Subsidiary of the Company that is incorporated in a non-US jurisdiction has, or at any time has had, an investment in “United States Property” within the meaning of
Section 956(c) of the Code. No Subsidiary of the Company that is or was organized or formed in a non-US jurisdiction is an “expatriated entity” within the meaning of Section 7874 of the
Code. No Subsidiary of the Company is or has been a “deferred foreign income corporation” within the meaning of Section 965(d) of the Code. Section 4.17 of the Disclosure Schedule sets forth the U.S. tax classification
(or any change in US tax classification) under U.S. federal income Tax Law of each Subsidiary of the Company from the date of it organization or formation through the Closing Date. For purposes of this Section 4.17, references to the
Company or any Subsidiary thereof shall include any entity that was merged with or liquidated or converted into the Company or Subsidiary thereof. The Company and each Subsidiary of the Company is in material compliance with transfer pricing Laws,
including the use of an arm’s length or similar amount for related person charges. This Section 4.17 and Section 4.15 (to the extent such section relates to Taxes) constitute the exclusive representations and warranties of the
Company with respect to Taxes and any claim for breach of representation with respect to Taxes shall be based solely on the representations made in such sections and shall not be based on the representations set forth in any other provision of
this Agreement. Nothing in this Section 4.17 or otherwise in this Agreement shall be construed as a representation or warranty with respect to (i) the amount or availability of any net operating loss, capital loss, or Tax credits, of the
Company in any taxable period (or portion thereof) beginning after the Closing Date or (ii) any Tax position that Buyer or its Affiliates (including Parent and the Company) may take in respect of any taxable period (or portion thereof)
beginning after the Closing Date. 
 4.18. Insurance. The Company has in full force and effect (a) fire and casualty insurance
policies sufficient in amount (subject to reasonable deductibles) to allow them to replace any of their properties that might be damaged or destroyed and (b) all insurance policies required to be held by the Company pursuant to applicable Law.
Section 4.17 of the Disclosure Schedules sets forth a list of all policies of fire, casualty, general liability, worker’s compensation, vehicular, clinical trial or any other insurance held by the Company and all of such policies are in
full force and effect and are from established insurers of recognized responsibility insuring against such losses and risks. The Company is not in default with respect to any material provision contained in any such policy and has not failed to give
any notice or present any material claim of which it has notice under any such policy in a timely fashion. All such policies are in full force and effect in accordance with their terms. The Company has not received or given a notice of cancellation
or nonrenewal with respect to any such policy and all premiums for such policies have been paid when due. There is no claim pending by the Company under any insurance policy set forth in Section 4.17 of the Disclosure Schedules as to which
coverage has been questioned, denied or disputed by the underwriters of such policy. 

  
 31 

 4.19. Related Party Transactions. 

(a) (i) None of (A) the Related Companies, (B) the employees, officers, managers, or directors of the Company, to the
Seller’s Knowledge, any member of such Person’s immediate family, or any corporation, partnership or other entity in which such Person is an officer, director, member or partner, or in which such Person has a controlling ownership interest
or otherwise controls (each such Person set forth in this clause (B), a “Related Party”), is, in the case of either clause (A) or clause (B), indebted to the Company, nor does the Company have any Indebtedness to any of them
and (ii) none of the Related Parties has any direct or indirect ownership interest in any Person with which the Company is Affiliated (including any Related Company) or with which the Company has a business relationship, or any Person that
competes with the Company, except that employees, officers, or directors of the Company and members of such Related Party’s immediate families may own non-controlling interests in the stock of publicly
traded companies that may compete with the Company. 
 (b) Except as set forth in Section 4.19(b) of the Disclosure Schedules, none of
the Related Companies or any Related Party, is directly or, to the Company’s Knowledge, indirectly interested in any Material Contract. All Contracts set forth in Section 4.9(vii) of the Disclosure Schedules, have been negotiated and
conducted in good faith and on an arms’ length basis. 
 4.20. Books and Records. 

(a) The Company maintains accurate Books and Records reflecting its assets and liabilities, and maintains proper and effective internal control
over financial reporting that provides reasonable assurance that (i) transactions are executed with the authorization of the Company’s management, (ii) transactions are recorded as necessary to permit preparation of the Company’s
financial statements, (iii) access to the Company’s assets is permitted only in accordance with the authorization of the Company’s management, (iv) the reporting of assets of the Company is compared with existing assets at
regular intervals and (v) proper and adequate procedures are implemented to effect the collection of accounts, notes and other receivables on a current and timely basis. 

(b) The resolutions of the boards of directors or meetings of stockholders of the Company and the share ledgers or other similar records of the
Company contain accurate records of (i) the issued and outstanding shares of the Company since the date of the Company’s formation, (ii) the current shareholdings in the Company and (iii) all proceedings of the Company’s
board of directors or general meetings of stockholders. 

  
 32 

 (c) At the Closing, all of the Books and Records of the Company will be in the possession of
the Company. The Seller has made available to the Buyer true, complete and correct copies of all management letters and letters to or from the Company’s accountants, if any, relating to any audit or review of the financial statements or Books
and Records of the Company. The Seller has reported to Buyer in writing any fraud Known to the Seller, whether or not material, that involves management or other employees who participate in the preparation of the Company’s financial statements
or have a significant role in the maintenance of the Books and Records. 
 (d) Section 4.20(d) of the Disclosure Schedules contains a
true and complete list of all powers of attorney granted by the Company that remain in force as of the date hereof, other than powers of attorney granted in the ordinary course of business consistent with past practice. The Company has not granted
to any Person any authority (whether express, implied or ostensible), which remains in effect as of the date hereof, to enter into any Contract or to incur any obligation or liability on behalf of the Company, other than those powers of attorney
granted to officers, directors, managers or employees of the Company to enter into Contracts in the ordinary course of business consistent with past practice. 

4.21. Regulatory Matters. With respect to each of the product candidates of the Company or otherwise in connection with the Company:

 (a) Neither the Company, nor the Seller has received any written notice from any Governmental Authority or any other Person alleging or
asserting noncompliance with any applicable Law. There are no enforcement actions pending or threatened by or on behalf of any Governmental Authority, and, to the Seller’s Knowledge, no circumstances exist that would reasonably form the basis
of any such Action. The Company has made all notifications, submissions, applications and reports required by applicable Law. All material notifications, submissions, applications, and reports submitted by the Company to any Governmental Authority
were true, complete and free of fraudulent or misleading statements in all material respects at the time made. To the Seller’s Knowledge, no basis for liability exists with respect to any such notification, submission, applications, or report.

 (b) All studies, including non-clinical laboratory studies, animal studies, tests, preclinical
trials, and clinical trials, conducted by or on behalf of, or sponsored by, the Company were and, to the extent still pending, are being, conducted in material compliance with applicable Laws and with experimental protocols, procedures and controls
and accepted professional scientific research standards. Neither the Company, nor the Seller has received any notices or correspondence from any Governmental Authority or any institutional review board or similar organization overseeing the conduct
of clinical or other studies requiring or requesting the termination, suspension or material modification of any such study, test or trial. 

4.22. No Brokers. None of Seller, Kranzler or the Company has engaged, or authorized to act on their behalf, any broker, agent, finder,
or similar representative such that the Buyer or the Company (following the Closing) will be liable for any brokerage commissions, finders’ fees or similar commissions in connection with the transactions contemplated by this Agreement. 

4.23. Disclosure. True, complete and accurate copies of all documents referred to in this Agreement as having been delivered or made
available to Buyer, including any documents referenced in the Disclosure Schedules have been delivered to Buyer. To the Knowledge of the Seller, none of the representations or warranties of the Seller contained in this Agreement or in the Schedules
or Exhibits delivered by the Seller pursuant hereto contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the representations or warranties, in the context in
which made, not false or misleading. 

  
 33 

 ARTICLE V. 

REPRESENTATIONS AND WARRANTIES OF THE BUYER 

The Buyer represents and warrants to Seller, as of the date hereof, as follows: 

5.1. Organization and Power. Buyer is a corporation, duly organized and validly existing under the laws of Delaware. The Buyer has all
requisite corporate power and corporate authority to execute and deliver this Agreement and the other agreements contemplated hereby and to perform its obligations hereunder and thereunder. 

5.2. Authorization. The execution, delivery and performance by the Buyer of this Agreement, the other agreements contemplated hereby to
which Buyer is a party and each of the transactions contemplated hereby or thereby have been duly authorized by all necessary corporate action on the part of the Buyer. This Agreement has been duly executed and delivered by the Buyer and this
Agreement constitutes, and each of the other agreements contemplated hereby upon execution and delivery by the Buyer will constitute, a valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as
the enforcement may be affected by the General Enforceability Exceptions. 
 5.3. No Violation. 

(a) The execution, delivery and performance by the Buyer of this Agreement and the other agreements contemplated hereby to which the Buyer is
party and the consummation of each of the transactions contemplated hereby and thereby will not (i) violate or conflict with any provision of the certificate of incorporation or bylaws (or similar governing documents) of the Buyer,
(ii) violate any Law or Order to which the Buyer is subject or (iii) violate, breach or constitute a default under or give rise to a right of termination, modification, cancellation or acceleration of any right or obligation of the Buyer
under, or result in the creation of a Lien on any of the properties or assets of the Buyer pursuant to, any provision of any agreement, contract, note, bond, mortgage, indenture, or lease or other instrument binding upon the Buyer or any license,
franchise, permit or other similar authorization held by the Buyer. 
 (b) The execution, delivery and performance by the Buyer of this
Agreement and the consummation of each of the transactions contemplated hereby do not require Buyer to obtain any authorization, consent, approval, exemption or other action from or to provide notice to any Governmental Authority or other Person
except, in each case, for such authorizations, consents, permits, approvals, exemptions, other actions or notices which, if not obtained or provided, would not reasonably be expected to have, individually or in the aggregate, an adverse effect on
Buyer’s ability to consummate the transactions contemplated hereby or to perform its obligations hereunder. 
 5.4. Litigation.
There are no Actions pending, or, to Buyer’s Knowledge, threatened against or affecting Buyer, seeking to restrict the purchase by Buyer of the Purchased Shares or which would otherwise adversely affect Buyer’s ability to consummate the
transactions contemplated by this Agreement. 

  
 34 

 5.5. Independent Investigation. Buyer has conducted its own independent
investigation, review and analysis of the business, results of operations, prospects, condition (financial or otherwise) or assets of the Company and its Subsidiaries, and acknowledges that it has been provided access to the personnel, properties,
assets, premises, books and records, and other documents and data of Seller and the Company for such purpose. Buyer acknowledges and agrees that: (a) in making its decision to enter into this Agreement and to consummate the transactions
contemplated hereby, Buyer has relied solely upon (1) its own investigation, (2) the express representations and warranties set forth in ARTICLE III and of Seller set forth in ARTICLE IV of this Agreement (including the related portions of
the Disclosure Schedules) and the other certificates, documents and instruments delivered by or on behalf of the Seller pursuant to the terms of this Agreement, and (3) the other covenants, promises and agreements contemplated by this
Agreement; and (b) none of Seller, the Company or any other Person has made any representation or warranty as to Seller, the Company or this Agreement, except as expressly set forth in ARTICLE III and ARTICLE IV of this Agreement (including the
related portions of the Disclosure Schedules) or in any certificate, document or instrument delivered by or on behalf of the Seller pursuant to the terms of this Agreement. 

ARTICLE VI. 

COVENANTS AND OTHER AGREEMENTS 

6.1. [Reserved]. 
 6.2.
Further Assurances. From and after the Closing, each of the Buyer and the Seller shall execute and deliver such further instruments of conveyance and transfer and use their respective commercially reasonable efforts to take promptly such
other action as reasonably may be necessary to further effectuate the transactions contemplated hereby or otherwise to carry out the intent and purposes of this Agreement. 

6.3. Expenses. Except as otherwise set forth in this Agreement, each party to this Agreement shall be solely responsible for and shall
bear all of its own costs and expenses incident to its obligations under and in respect of this Agreement and the transactions contemplated hereby, including any such costs and expenses incurred by any party in connection with the negotiation,
preparation and performance of and compliance with the terms of this Agreement (including the fees and expenses of legal counsel, accountants, investment bankers or other representatives and consultants), whether or not the transactions contemplated
hereby are consummated. For the avoidance of doubt, any costs or expenses incurred in connection with the development of the Product Candidates, including the creation of a Clinical Development Plan shall be expenses of the Company or Parent
following the Closing and shall not be deemed cost or expenses related to this Agreement. 

  
 35 

 6.4. Tax Matters. 

(a) Notwithstanding anything to the contrary herein, each of the Buyer, on the one hand, and Seller, on the other hand, shall pay one-half of all transfer, documentary, sales, use, stamp, registration and other such Taxes, and all conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in
connection with the execution and delivery of this Agreement, and the consummation of each of the transactions contemplated by this Agreement. After the Closing, the Buyer shall, or shall cause the Company to, prepare and file all necessary Tax
Returns and other documentation with respect to all such Taxes, fees and charges; provided, however, that Seller shall have the right to examine such Tax Returns and other documentation no less than five (5) Business Days prior to
filing. 
 (b) For any taxable period of the Company that includes (but does not end on) the Closing Date (any such taxable period, a
“Straddle Period”) or that ends on or before the Closing Date for which any Tax Returns by the Company are due after the Closing Date, the Buyer will timely prepare and file with the appropriate Taxing Authority all Tax Returns
required to be filed by or with respect to the Company and any of its Subsidiaries (collectively, the “Company Tax Returns”) and will, subject to the rights of the Buyer Indemnitees pursuant to Section 8.1(b)(iv), pay all Taxes
due with respect to such Company Tax Returns. Any Company Tax Return to be prepared and filed for any Pre-Closing Tax Period shall be prepared on a basis consistent with the prior Tax Returns of the Company or
its Subsidiary, as applicable, and no position shall be taken, election made or method adopted that is inconsistent with positions taken, elections made or methods used by the Company or such Subsidiary in prior periods in filing such Tax Returns,
unless otherwise required pursuant to applicable Law. To the maximum extent permitted by applicable Law, all Transaction Deductions will be treated as properly allocable to the taxable period ending as of the end of the Closing Date and will be
included as deductions on the Tax Returns of the Company that include such period. Parent and Buyer agree to file all Tax Returns (and unless otherwise required by applicable Law, will not take any position inconsistent therewith upon examination of
any such Tax Return, in any examination, audit, or other proceeding with respect to such Tax Returns) consistent with the preceding sentence. Parent and Buyer shall provide the Seller with a copy of each Company Tax Return (and such additional
information regarding such Tax Return as may reasonably be requested by the Seller) for review and comment at least thirty (30) days prior to the filing of such Company Tax Return, in the case of income Tax Returns (or if such Tax Returns are
due within forty-five (45) days of the Closing Date, as soon as reasonably practicable after the Closing Date), and in such period of time prior to filing as Parent shall reasonably determine to be practicable in the case of other Company Tax
Returns. Parent and Buyer shall consider in good faith all timely-received, reasonable comments of the Seller to such Company Tax Returns. 

(c) Parent, Buyer and the Seller agree that if the Company is permitted but not required under applicable U.S. federal Law to treat the
Closing Date as the last day of a taxable period, Parent, Buyer and the Seller shall treat such day as the last day of a taxable period of the Company. For purposes of determining the amount of Taxes that are payable for a Straddle Period, the
portion of such Taxes which relate to the Pre-Closing Tax Period shall: (i) in the case of Taxes such as real and personal ad valorem taxes and other similar Taxes imposed on a periodic basis that, in
each case, are not described in clause (ii), be deemed to be the amount of such Taxes for the entire Straddle Period multiplied by the fraction the numerator of which is the number of days 

  
 36 

 
in the Straddle Period ending on and including the Closing Date (at the end of such Closing Date), and the denominator of which is the number of days in the entire Straddle Period; and
(ii) in the case of Taxes based on or measured by income, gross or net sales, payments or receipts, be deemed equal to the amount of Taxes which would be payable if the relevant Straddle Period ended on and included the Closing Date (at the end
of such Closing Date); provided, however, that any item of deduction or loss determined on an annual or periodic basis (such as deductions for depreciation) shall be apportioned on a daily basis. 

(d) Buyer will have the responsibility for, and the right to control any audit, litigation or other proceeding with respect to Taxes or Tax
Returns of the Company (each, a “Tax Claim”); provided, however, that, with respect to any Tax Claim that relates in whole or in part to any Pre-Closing Tax Period and to Taxes for which the
Seller may be liable (including pursuant to this Agreement), the Seller shall have the right to review in advance and comment upon all submissions made in the course of such Tax Claims (including any administrative appeals thereof), and the
Seller’s consent (not to be unreasonably withheld, delayed or conditioned) shall be required for any settlement of such Tax Claims by Buyer that could reasonably affect the liability of the Seller pursuant to this Agreement. Notwithstanding
anything to the contrary in this Agreement, the conduct of any Tax Claim shall be governed by this Section 6.4(d) and not Section 8.6. 

(e) Buyer and the Company will not (and will not permit their respective Affiliates, including Parent and Company’s Subsidiaries,
to) (i) except for Tax Returns prepared and filed in accordance with Section 6.4(b), file or amend any Tax Returns of the Company or its Subsidiaries with respect to any Pre-Closing Tax Period,
(ii) with respect to Tax Returns prepared and filed in accordance with Section 6.4(b) after the date such Tax Returns are filed, amend any such Tax Returns, (iii) make or change any Tax election or change any method of accounting that
has retroactive effect to any Tax Return of the Company or any of its Subsidiaries for a Pre-Closing Tax Period (including any election pursuant to Section 338 or 336 of the Code), or
(iv) voluntarily approach any Taxing Authority regarding any Tax or Tax Return of the Company or any of its Subsidiaries for a Pre-Closing Tax Period, in each case, except (1) as required by
applicable Law (provided that Buyer, the Company or their applicable Affiliate shall have consulted in good faith with the Seller regarding the requirements of applicable Law before taking any action pursuant to this Section 6.4(e))or
(2) with the prior written consent of Seller (such consent not to be unreasonably withheld, conditioned or delayed). 
 (f) For
U.S. federal income Tax purposes (and state and local Tax purposes where applicable), Parent, Buyer, the Company, and the Seller intend that (i) the contribution of cash by ATAI Life Sciences AG to Parent in exchange for capital stock of
Parent and (ii) the contribution of the Rollover Shares to Parent by the Seller in exchange for Parent Shares, as set forth in the Rollover Agreement, be collectively treated as a single interrelated transaction that qualifies as an exchange
described in Section 351(a) of the Code. Parent, Buyer, the Company and their Affiliates shall not cause or allow Buyer to be liquidated, merged, or converted into a limited liability company for at least two (2) calendar years following
the Closing or otherwise enter into a transaction pursuant to which Buyer ceases to exist as a separate entity treated as a corporation for U.S. federal income tax purposes (and applicable state and local tax purposes) collectively referred to
as Liquidation Transactions) during such two (2) calendar year period, unless Parent obtains from a nationally recognized law firm a written opinion addressed to Parent (with Seller as an intended third party beneficiary) opining
that such Liquidation Transaction 

  
 37 

 
“should” not adversely affect the Rollover qualifying as a tax-free exchange under Section 351(a) of the Code, and shall act in accordance
with the treatment of the Rollover as a transaction which, together with the contribution of cash by ATAI Life Sciences AG to Parent, qualifies as a tax-free exchange under Section 351(a) of the Code in
the filing of all Tax Returns and in the course of any Tax Claim relating thereto and shall take no position inconsistent with such treatment, unless otherwise required by applicable Law. 

(g) Except as may be required pursuant to a “determination” (as defined in Section 1313 of the Code or any similar provision of
state, local, or foreign Tax Law), for all applicable Tax purposes, Parent, Buyer and Seller agree to treat, and no party shall take any action or filing position inconsistent with treating, all consideration payable to Seller pursuant to
Section 2.1(b) (including any Contingent Payments) as payments to Seller in respect of the Purchased Shares. 
 (h) Buyer, Parent, the
Company, Seller and any Affiliate thereof shall use commercially reasonable efforts to cooperate fully, as and to the extent reasonably requested by the other parties, in connection with the preparation and filing of any Tax Returns and any audit,
litigation or other proceeding with respect to Taxes relating to the Company or its Subsidiaries. Such cooperation shall include the retention and (upon the other party’s request) the provision of records and information which are in such
parties possession and are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. 

6.5. Confidentiality. 
 (a)
Each party acknowledges that confidential information provided to it by the other party, is subject to the terms of a confidentiality agreement, dated August 19, 2018, between the Company and an Affiliate of the Buyer (the
“Confidentiality Agreement”), the terms of which are incorporated herein by reference. Effective as of the Closing, the Confidentiality Agreement shall terminate with respect to information relating solely to the Company;
provided, however, that the Buyer acknowledges and agrees that any and all other information provided to it by or on behalf of the Seller concerning the Seller shall remain subject to the terms and conditions of the Confidentiality
Agreement after the Closing Date. 
 (b) Seller shall keep confidential, and cause its controlled Affiliates and its and their officers,
directors, managers, employees and advisors to keep confidential, all information relating to the Company provided to Seller or to which Seller had access on or prior to the Closing Date, except as required by Law and except for information that is
publicly available or becomes publicly available other than as a result of a breach of this Section 6.5(b); provided, that Seller shall be permitted to disclose such Company information to Seller’s accountants, attorneys and other advisors
to the extent necessary to provide business or financial advice to Seller; provided, further, that such accountant, attorney or other advisor is bound by professional duties or Contractual obligations to keep such information confidential. 

(c) Seller hereby assigns, to the extent such assignment is permitted pursuant to the terms thereof, effective as of the Closing, to the Buyer
its rights under all confidentiality agreements entered into by Seller with any Person in connection with the proposed sale of the Company to the extent such rights relate to the Company. 

  
 38 

 6.6. Intentionally Omitted. 

6.7. Release of Claims. EFFECTIVE AS OF THE CLOSING, SELLER DOES HEREBY FOR ITSELF AND ITS RESPECTIVE AFFILIATES, PARTNERS, HEIRS,
BENEFICIARIES, SUCCESSORS AND ASSIGNS, IF ANY, RELEASE AND ABSOLUTELY FOREVER DISCHARGE THE COMPANY AND ITS OFFICERS, DIRECTORS, MANAGERS, MEMBERS, STOCKHOLDERS, AFFILIATES, EMPLOYEES (IF ANY) AND AGENTS (EACH, A “RELEASED PARTY”) FROM AND
AGAINST ANY AND ALL CLAIMS, DEMANDS, DAMAGES, DEBTS, LIABILITIES, OBLIGATIONS, COSTS, EXPENSES (INCLUDING ATTORNEYS’ AND ACCOUNTANTS’ FEES AND EXPENSES), ACTIONS AND CAUSES OF ACTION OF ANY NATURE WHATSOEVER, WHETHER NOW KNOWN OR UNKNOWN,
SUSPECTED OR UNSUSPECTED, THAT SUCH PERSON NOW HAS, OR AT ANY TIME PREVIOUSLY HAD, OR SHALL OR MAY HAVE IN THE FUTURE, AS HOLDER OF ANY SECURITIES OF THE COMPANY, ARISING BY VIRTUE OF OR IN ANY MATTER RELATED TO ANY ACTIONS OR INACTIONS WITH RESPECT
TO THE COMPANY OR THEIR AFFAIRS WITH RESPECT TO THE COMPANY ON OR BEFORE THE CLOSING DATE (“RELEASED MATTERS”); PROVIDED, THAT THIS RELEASE SHALL NOT EXTEND TO ANY RIGHT OF SELLER (1) UNDER THIS AGREEMENT, THE EMPLOYMENT AGREEMENT,
THE STOCKHOLDERS AGREEMENT OR THE SPORN ROLLOVER AGREEMENT, (2) WITH RESPECT TO WAGES OR EMPLOYEE BENEFITS ACCRUED AS OF THE CLOSING ARISING FROM OR IN CONNECTION WITH SELLER’S EMPLOYMENT BY THE COMPANY PRIOR TO THE CLOSING, OR
(3) UNDER DIRECTOR AND OFFICER INDEMNIFICATION PROVISIONS SET FORTH IN THE ORGANIZATIONAL DOCUMENTS OR OTHER AGREEMENTS OF THE COMPANY AND ITS SUBSIDIARIES AS IN EFFECT ON THE DATE HEREOF. IT IS THE INTENTION OF THE SELLER IN EXECUTING THIS
RELEASE AND IN GIVING AND RECEIVING THE CONSIDERATION CALLED FOR HEREIN, THAT THE RELEASE CONTAINED IN THIS SECTION 6.7 SHALL BE EFFECTIVE AS A FULL AND FINAL ACCORD AND SATISFACTION AND GENERAL RELEASE OF AND FROM ALL RELEASED MATTERS AND THE FINAL
RESOLUTION BY SELLER AND THE RELEASED PARTIES OF ALL RELEASED MATTERS. SELLER HEREBY REPRESENTS TO THE BUYER AND THE COMPANY THAT SELLER HAS NOT VOLUNTARILY OR INVOLUNTARILY ASSIGNED OR TRANSFERRED OR PURPORTED TO ASSIGN OR TRANSFER TO ANY
PERSON ANY RELEASED MATTERS AND THAT NO PERSON OTHER THAN SELLER HAS ANY INTEREST IN ANY RELEASED MATTER BY LAW OR CONTRACT BY VIRTUE OF ANY ACTION OR INACTION BY SELLER. THE INVALIDITY OR UNENFORCEABILITY OF ANY PART OF THIS SECTION 6.7 SHALL NOT
AFFECT THE VALIDITY OR ENFORCEABILITY OF THE REMAINDER OF THIS SECTION 6.7, WHICH SHALL REMAIN IN FULL FORCE AND EFFECT. 

  
 39 

 ARTICLE VII. 

[RESERVED] 

ARTICLE VIII. 

INDEMNIFICATION 

8.1. Indemnification by Seller. 

(a) Subject to the applicable limitations in this ARTICLE VIII, from and after the Closing, Seller shall indemnify and hold harmless the Buyer,
the Company and its Subsidiaries, and the officers, directors and employees (in the case of such officers, directors and employees, acting in their capacity as such) of the Buyer, the Company and the Company’s Subsidiaries (each a
“Buyer Indemnitee” and collectively, the “Buyer Indemnitees”) against any and all losses, fines, monetary penalties, Taxes, monetary damages, fees, obligations, claims of any kind, costs or expenses (including court
costs, reasonable outside legal and accounting, and reasonable outside professional services expenses and costs incurred in connection with an Action to the extent such Action arises out of or results from the indemnifiable matters specified in this
ARTICLE VIII) (each a “Loss” or collectively, “Losses”) that any Buyer Indemnitee suffers, sustains or incurs to the extent arising out of or as a result of: 

(i) any inaccuracy or breach, as of the date of this Agreement (or, in the case of a representation or warranty made as of a
particular date, as of such date) of a representation or warranty made by Seller in ARTICLE III or in any Schedule or Exhibit required to be delivered by Seller (in Seller’s capacity as Seller hereunder) pursuant hereto (it being
agreed and acknowledged by the parties that for purposes of the right to indemnification pursuant to this Section 8.1(a)(i), such representations and warranties of Seller shall not be deemed qualified by any references herein or therein to
materiality for purposes of determining the amount of Loss attributable to a breach thereof; provided, that such materiality qualifications and references shall be given their full effect for purposes of determining whether a breach or inaccuracy
has occurred; provided, further, that all references to materiality shall be given their full effect to the extent a representation or warranty requires disclosure of a list of items of a material nature or above a specified threshold or where such
representation or warranty would otherwise be rendered meaningless by disregarding materiality references); and 
 (ii) any
breach of any covenant or agreement made by Seller in this Agreement. 
 (b) Subject to the applicable limitations in this ARTICLE VIII, from
and after the Closing, Seller shall indemnify and hold harmless the Buyer Indemnitees against Seller’s Pro- Rata Share of any and all Losses (i.e., 80% of any such Loss or Losses) that any Buyer
Indemnitee suffers, sustains or incurs to the extent arising out of or as a result of: 

  
 40 

 (i) any inaccuracy or breach as of the date of this Agreement (or, in the
case of a representation or warranty made as of a particular date, as of such date) of any representation or warranty made by the Seller regarding the Company contained in ARTICLE IV or in any Schedule or Exhibit required to be delivered
by the Seller pursuant thereto (it being agreed and acknowledged by the parties that for purposes of the right to indemnification pursuant to this Section 8.1(b)(i), such representations and warranties of the Seller regarding the Company shall
not be deemed qualified by any references herein or therein to materiality or to whether or not any such breach results or would reasonably be expected to result in a Material Adverse Effect for purposes of determining the amount of Loss
attributable to a breach thereof; provided, that such materiality or Material Adverse Effect qualifications and references shall be given their full effect for purposes of determining whether a breach or inaccuracy has occurred; provided, further,
that all references to materiality shall be given their full effect to the extent a representation or warranty requires disclosure of a list of items of a material nature or above a specified threshold or where such representation or warranty would
otherwise be rendered meaningless by disregarding materiality or Material Adverse Effect references); 
 (ii) [Intentionally
Omitted]; 
 (iii) any (A) Company Transaction Expenses to the extent unpaid following the Closing or (B) any
Closing Liabilities to the extent unpaid following the Closing, in each such case, except to the extent otherwise taken into account as a dollar-for-dollar adjustment to
the Closing Cash Consideration; 
 (iv) any Taxes which Seller has agreed to pay pursuant to Section 6.4(a) and all Pre-Closing Taxes; and 
 (v) any Action by a stockholder or former stockholder of the
Company, or by any other Person or Governmental Authority, to the extent asserting: (A) ownership or rights to ownership of any shares of capital stock of the Company at any time prior to the Closing; (B) any right of a stockholder of the
Company with respect to any action or omission occurring prior to the Closing (other than the right to receive the applicable amounts payable as provided for hereunder), including any option, preemptive right or right to notice or to vote;
(C) with respect to any action or omission occurring prior to the Closing, any right under the certificate of incorporation or By-laws of the Company, each as in effect on the date hereof; or (D) any
claim that its shares were wrongfully purchased by the Buyer in connection with the transactions contemplated hereby to occur at the Closing. 

(c) No Buyer Indemnitee (other than the Buyer or any successor or, subject to Section 9.3, permitted assignee of the Buyer) shall be
entitled to assert any indemnification claims pursuant to this Section 8.1 or exercise any other remedy under this Agreement; provided, that, subject to the limitations set forth in this Agreement, Buyer may exercise such rights hereunder on
behalf of such Buyer Indemnitee. 

  
 41 

 8.2. Indemnification by the Buyer. Subject to the applicable limitations in this
ARTICLE VIII, from and after the Closing, the Buyer shall indemnify and hold harmless Seller (a “Seller Indemnitee” and collectively with the Buyer Indemnitees, the “Indemnitees” and each an
“Indemnitee”) against any and all Losses that Seller suffers, sustains or incurs to the extent arising out of or as a result of: 

(a) any inaccuracy or breach as of the date of this Agreement (or, in the case of a representation or warranty made as of a particular date, as
of such date) of a representation or warranty made by the Buyer in ARTICLE V or in any Schedule or Exhibit required to be delivered by the Buyer pursuant to the terms hereof (it being agreed and acknowledged by the parties that for
purposes of the right to indemnification pursuant to this Section 8.2(a), such representations and warranties of Buyer shall not be deemed qualified by any references herein or therein to materiality for purposes of determining the amount of
Loss attributable to a breach thereof; provided, that such materiality qualifications and references shall be given their full effect for purposes of determining whether a breach or inaccuracy has occurred; provided, further, that all references to
materiality shall be given their full effect to the extent a representation or warranty requires disclosure of a list of items of a material nature or above a specified threshold or where such representation or warranty would otherwise be rendered
meaningless by disregarding materiality references); and 
 (b) any breach of any covenant or agreement made by the Buyer in this Agreement.

 8.3. Indemnity Survival Dates. The representations and warranties contained in this Agreement or in any certificate or other
writing delivered pursuant hereto or in connection herewith shall survive the Closing until the one (1) year anniversary of the Closing Date; provided, that (a) the representations and warranties set forth in Section 3.1 (Power
and Authorization), Section 3.2 (No Violation) and Section 3.3 (Ownership of Shares) and the Fundamental Representations (the representations in such Sections 3.1, 3.2 and 3.3 together with the Fundamental Representations, the
“Specified Representations”) shall survive until the earlier of (1) the date that is three years following the Closing Date, and (2) the expiration of the statute of limitations applicable to the matters set forth in such
representations and warranties (after giving effect to any waiver, modification, tolling or extension thereof) and (b) the representations and warranties set forth in Section 4.17 (Tax Matters) and the covenants in Section 6.4 shall
survive until thirty (30) days following the expiration of the statute of limitations applicable to the matters set forth in such representations and warranties (after giving effect to any waiver, modification, tolling or extension thereof). An
Indemnitee shall not be entitled to indemnification under Section 8.1(a)(i), Section 8.1(b)(i) or Section 8.2 unless a Claim Notice of a matter giving rise to the applicable breach of representation or warranty for which
indemnification is sought shall have been delivered to the Seller or the Buyer, as the case may be, on or before the expiration of the survival period applicable thereto, in which case such claim for indemnification shall survive the expiration of
such survival period until final resolution thereof. The covenants and agreements contained in this Agreement or in any certificate or other writing delivered pursuant hereto or in connection herewith shall survive the Closing indefinitely in
accordance with their terms until performed. It is the express intent of the parties hereto that, if an applicable survival period as contemplated by this Section 8.3 is shorter than the statute of limitations that would otherwise apply, then,
by contract, the applicable statute of limitations shall be reduced to the survival period contemplated hereby. The parties hereto further acknowledge that the time periods set forth in this Section 8.3 for the assertion of claims under this
Agreement are the result of arms’-length negotiation among the parties hereto and that they intend for the time periods to be enforced as agreed by the parties hereto. 

  
 42 

 8.4. Additional Indemnification Limitations. The indemnification provided for in
Section 8.1 above is subject to each of the following additional limitations: 
 (a) Buyer Indemnification Basket. No Buyer
Indemnitee shall be entitled to assert any claim for indemnification under Section 8.1(a)(i) or Section 8.1(b)(i) (other than in connection with any inaccuracy or breach of a Specified Representation, as to which this limitation shall not
apply) (i) unless and until, individually or in the aggregate, all Losses in respect of indemnification under Section 8.1(a)(i) and Section 8.1(b)(i) exceed Twenty-Five Thousand Dollars ($25,000) (the “Basket”), it
being understood that once such amount is exceeded, only the amount of such claims in excess of the Basket shall be considered indemnifiable Losses to which Buyer is entitled hereunder. For the avoidance of doubt, the foregoing shall not apply to
any claim for indemnification under Section 8.1(a)(i) (with respect to any inaccuracy or breach of a Specified Representation or tax representations in Section 4.17)), Section 8.1(a)(ii), Section 8.1(b)(i) (with respect to any
inaccuracy or breach of a Specified Representation) or Sections 8.1(b)(ii) through 8.1(b)(v) 
 (b) Buyer Indemnification Caps.

 (i) The aggregate liability of Seller under Section 8.1(a)(i) and 8.1(b)(i) (other than in connection with an
inaccuracy or breach of a Specified Representation and the representations in Section 4.17, as to which this limitation shall not apply) shall not exceed Four Hundred Thousand Dollars ($400,000). For the avoidance of doubt, the foregoing shall
not apply to any claim for indemnification under Section 8.1(a) (with respect to any inaccuracy or breach of a Specified Representation and the representations in Section 4.17), Section 8.1(a)(ii), Section 8.1(b)(i) (with respect
to any inaccuracy or breach of a Specified Representation) or Sections 8.1(b)(ii) through 8.1(b)(v). 
 (ii)
Notwithstanding Section 8.4(b)(i) or anything to the contrary in this Agreement, in no event shall the aggregate liability of Seller pursuant to Section 8.1(b)(ii) through (v) or any Specified Representation this Agreement and the
transactions contemplated hereby exceed the portion of Closing Cash Consideration actually paid to Seller pursuant to this Agreement; provided, that the foregoing limitation shall not apply (but still subject to all other limitations set forth in
this Agreement) with respect to Losses suffered by Buyer Indemnitees to the extent arising out of or as a result of Seller Fraud committed by Seller. 

  
 43 

 (c) No Duplicate Recovery; Insurance Proceeds. 

(i) Despite any contrary provision of this Agreement, neither the Buyer Indemnitees (whether individually or collectively) nor
Seller (whether individually or collectively) are entitled to recover more than once with respect to any individual Loss under a claim for indemnification pursuant to this ARTICLE VIII or any adjustment to the consideration payable pursuant to
ARTICLE II, and no duplicate payment, reimbursement, indemnification, adjustment to such consideration or other form of recovery or remedy in respect of any such Loss is permitted. 

(ii) The amount of any Loss subject to indemnification under Section 8.1 or of any claim therefor will be calculated net
of any amounts actually recovered by the Buyer Indemnitees (including the Company or its Subsidiaries) under any applicable third party insurance policies that provide risk transfer coverage to the Buyer Indemnitees or the Company or its
Subsidiaries (but after taking into account any reasonable costs incurred by the Buyer Indemnitees in connection with recovering under any such policies and the aggregate increase in insurance premiums that are proximately caused by any such Loss).
In the event that any such third party insurance recovery is made by the Buyer Indemnitees with respect to any Loss for which any such Buyer Indemnitee has been indemnified hereunder and received payment from the Seller therefor (including, for the
avoidance of doubt, by way of off-set pursuant to Section 2.3(c)), then the Buyer shall pay to the Seller, a refund (net of any reasonable costs incurred by the Buyer Indemnitees in connection with
recovering under such policies and the aggregate increase in insurance premiums that are proximately caused by any such Loss) in an amount equal to the excess (if any) of (A) (I) the amount paid by the Seller to such Buyer Indemnitees in
respect of such Loss plus (II) the amount of such insurance recovery by the Buyer Indemnitees over (B) the full amount of such Loss. Subject to the limitations set forth in this Section 8.4(c)(ii), to the extent insurance policies of
the type described in this Section 8.4(c)(ii) are in place and would reasonably be expected to provide coverage with respect to a Loss for which Seller is obligated to provide indemnity hereunder, Buyer shall (and shall cause any other Buyer
Indemnitees, as applicable) to use its commercially reasonable efforts to assert claims for coverage under such policies in respect of such Losses. For the avoidance of doubt, no recovery under any insurance policies issued by (A) an insurer
that is an Affiliate of the Buyer or any of its Affiliates or (B) a commercial insurer as a “fronted” policy with no expectation of providing the insured(s) with risk transfer coverage shall be subject to this Section 8.4(c)(ii).

 8.5. Punitive and Certain Other Damages. Notwithstanding anything herein to the contrary, no Indemnitee will be entitled to
indemnification for any punitive damages or Losses or any consequential damages or Losses that would not be reasonably foreseeable as a result of (and at the time of occurrence of) the breach or other specified event hereunder giving rise to the
relevant Loss, except in any case, to the extent such damages are finally awarded by a court of competent jurisdiction or, if applicable, in final, binding, non-appealable arbitration, in connection with a
Third Party Claim. 

  
 44 

 8.6. Claims Notices; Third Party Claims. 

(a) In order to assert a claim for indemnity pursuant to this ARTICLE VIII (whether in respect of a Third Party Claim or a direct claim), the
Buyer or Seller, as applicable (such party seeking indemnification hereunder, the “Indemnified Party”) shall, within the applicable time periods set forth in Section 8.3 deliver to the Indemnitee a written notice (a
“Claim Notice”) (i) stating that the Indemnified Party has incurred, paid or reasonably expects, in good faith, that it will incur Losses for which Indemnitee is responsible hereunder; (ii) stating the amount of such Losses
(which, in the case of Losses not yet incurred or paid may be the maximum amount believed by the Indemnified Party in good faith to be incurred, paid by and owed to a third party); and (iii) specifying in reasonable detail (based upon the
information then possessed by the Indemnified Party) the individual items of such Loss included in the amount so stated and the nature of the claim to which such Losses are related. 

(b) In the event the Buyer becomes aware of a pending or threatened claim or demand by a third party that the Buyer has determined has given or
would reasonably be expected to give rise to a right of indemnification under this Agreement (such claim or demand being a “Third Party Claim” and including a pending or threatened claim or demand asserted by a third party against a
Buyer Indemnitee), the Buyer shall promptly deliver a Claim Notice to Seller. The Buyer Indemnitees alone shall control the defense of any Third Party Claim. The Seller may participate in, but not control, the defense of a Third Party Claim at its
own expense. The Buyer shall keep the Seller advised of the status of such Third Party Claim and the defense thereof and shall consider in good faith recommendations made by the Seller with respect thereto. Seller shall, upon reasonable written
request from Buyer, furnish the Buyer with such information as Seller may have (except to the extent that doing so would, in the reasonable belief of Seller, result in the waiver of attorney-client privilege, violation of Law or breach of Contract)
with respect to such Third Party Claim (including copies of any summons, complaint or other pleading which may have been served on such party and any written claim, demand, invoice, billing or other document evidencing or asserting the same) and
shall otherwise use commercially reasonable efforts to cooperate with and assist the Buyer Indemnitees in the defense of such Third Party Claim. In connection with matters for which the Buyer Indemnitees successfully obtain indemnification pursuant
to Section 8.1, the reasonable fees and expenses of counsel to the Buyer Indemnitees with respect to such Third Party Claim shall be considered Losses for purposes of this Agreement. Seller shall not agree to any settlement of, or the entry of
any judgment arising from, any Third Party Claim without the prior written consent of the Buyer, which shall not be unreasonably withheld, conditioned or delayed. The Buyer Indemnitees shall not agree to any settlement of, or the entry of any
judgment arising from, any such Third Party Claim without the prior written consent of the Seller, which shall not be unreasonably withheld, conditioned or delayed (it being agreed that such consent shall be deemed to be unreasonably withheld where
the settlement to which Buyer is being asked to consent consists of a firm offer to settle a Third Party Claim without leading to liability or the creation of a financial or other obligation on the part of Buyer Indemnitees and provides, in
customary form, for the unconditional release of each Buyer Indemnitee from all liabilities and obligations in connection with such Third Party Claim). 

8.7. Exclusive Remedy. Except for claims of or arising out of Seller Fraud to the extent such claims may, as a matter of Law, only be
recovered by alternative form of action, or as expressly provided in Section 9.11, the indemnification provisions in this ARTICLE VIII shall be the exclusive remedy of a Buyer Indemnitee (which after the Closing shall include the Company),
regardless of the theory or cause of action, with respect to claims made after the Closing under this Agreement or that relate to the transactions contemplated by this Agreement. For the avoidance of doubt, the foregoing provisions of this
Section 8.7 shall not preclude the Buyer Indemnitees from asserting other remedies to the extent such remedies are sought in respect of claims of Seller Fraud or from seeking non-monetary injunctive
relief pursuant to Section 9.11. 

  
 45 

 8.8. Tax Treatment of Indemnification Claims. Except as otherwise required by
applicable Law, the parties shall treat, for Tax purposes, any indemnification payment made hereunder as an adjustment to the consideration payable to Seller for the Purchased Shares pursuant to Section 2.1(b). 

ARTICLE IX. 

MISCELLANEOUS 

9.1. Amendment and Waiver. This Agreement may not be amended except by an instrument in writing signed by the Seller and the Buyer. At
any time after the Closing, Buyer, on the one hand, and the Seller, on the other hand, may, to the extent legally allowed, (A) extend the time for the performance of any of the obligations of the other owed to such party, (B) waive any
inaccuracies in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto or (C) waive any breaches of any of the covenants, agreements, obligations or conditions for the benefit of such
party contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing that is (1) with respect to Seller, signed by Seller and (2) with respect to Buyer, signed by the Buyer. The failure of any
party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights. 
 9.2.
Notices. All notices, requests, demands and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when
sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next Business Day, (c) five (5) days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, in each case to the following addresses, facsimile numbers
or e-mail addresses and marked to the attention of the person (by name or title) designated below (or to such other address, facsimile number, e-mail address or person
as a party may designate by notice to the other party): 
 If to the Buyer, to: 

ATAI US 2, Inc. 

c/o ATAI Life Sciences AG 

Barer Str 7 

80333 Munich, Germany 

Attn: [***] 
 with
a copy (which shall not constitute notice) to: 
 Dentons US LLP 

1221 Avenue of the Americas 

New York, NY 10020 

  
 46 

 Attention: [***] 

Telephone: [***] 

Email: [***] 
 If
to Seller, to: 
 Dr. Jonathan Sporn 

230 Riverside Drive, 19D 

New York, NY 10025 

with a copy (which shall not constitute notice) to: 

Cooley LLP 

500 Boylston Street, 14th Floor 

Boston, MA 02116-3736 

Attention: [***] 

Telephone: [***] 

Email: [***] 

9.3. Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of each the parties
hereto and their respective successors and assigns. Neither this Agreement nor any rights, benefits or obligations set forth herein may be assigned by any of the parties hereto; provided, however, that the Buyer shall be permitted to
assign its rights under this Agreement, or delegate its obligations under this Agreement, to any Affiliate of the Buyer (provided that the Buyer shall nonetheless remain liable for all of its obligations hereunder following such assignment). 

9.4. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement. 
 9.5. No Strict Construction. The language used in this Agreement
shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any Person. 

9.6. Captions. The captions used in this Agreement are for convenience of reference only and do not constitute a part of this Agreement
and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement, and all provisions of this Agreement shall be enforced and construed as if no caption had been used in this Agreement. 

9.7. No Third-Party Beneficiaries. Nothing herein expressed or implied is intended or shall be construed to confer upon or give to any
Person, other than the parties hereto and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement, such third parties specifically including employees or creditors of the Company;
provided, however, that the Buyer Indemnitees are intended third-party beneficiaries under ARTICLE VIII. 

  
 47 

 9.8. Complete Agreement. This Agreement and the documents referred to herein
(including the Rollover Agreement and the Stockholders Agreement) contain the complete agreement between the parties and supersede any prior understandings, agreements or representations by or between the parties, written or oral, which may have
related to the subject matter hereof in any way. 
 9.9. Counterparts. This Agreement may be executed in any number of counterparts,
and by the parties on separate counterparts, but shall not be effective until each party has executed at least one counterpart. Each counterpart shall constitute an original of this Agreement, but all of the counterparts shall together constitute
one and the same Agreement. The exchange of copies of this Agreement and of signature pages by facsimile transmission, PDF or other electronic file shall constitute effective execution and delivery of this Agreement as to the parties and may be used
in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile, PDF or other electronic file shall be deemed to be their original signatures for all purposes. 

9.10. Interpretation. References in this Agreement to any gender include references to all genders, and references to the singular
include references to the plural and vice versa. The words “include,” “includes” and “including,” when used in this Agreement, shall be deemed to be followed by the phrase “without limitation.” Unless the
context otherwise requires, references in this Agreement to Articles, Sections, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement. Unless the context otherwise
requires, the words “hereof,” “hereby” and “herein” and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Article, Section or provision of this
Agreement. The term “domestic” shall refer to the United States and the term “foreign” shall refer to any non-U.S. jurisdiction. The table of contents and headings contained in this
Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Any references to payments to be made hereunder or to dollars or $ shall be made in and means United States dollars. A
document being “made available to the Buyer,” being “provided to the Buyer” or other similar terms refers to the Company (a) making such document available to the Buyer or its counsel on a
CD-ROM, electronic data room or other electronic storage device prior to the date of this Agreement or (b) furnishing such document to the Buyer or its counsel at any time prior to the date of this
Agreement. Any item, information or facts disclosed in one section or subsection of the Disclosure Schedules will be deemed to be disclosed in all other applicable sections or subsections of the Disclosure Schedules as an
exception to the related representations and warranties solely to the extent the applicability of the matter so disclosed to such other representation or warranty is reasonably apparent from a reading of the disclosure. The disclosure of any matter
or item in the Disclosure Schedules will not be deemed to constitute an acknowledgement that any such matter or item is material or is required to be disclosed. Capitalized terms used and not otherwise defined in the Disclosure Schedules shall have
the meanings ascribed to such terms in this Agreement. 
 9.11. Specific Performance. Each of the parties to this Agreement
acknowledges and agrees that the other parties to this Agreement would be irreparably harmed in the event that any of the terms or provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached.
Therefore, except as otherwise expressly set forth in this Agreement, each of the parties to this Agreement hereby agrees that the other parties to this Agreement shall be entitled to an injunction or injunctions to prevent breaches of any of the
terms 

  
 48 

 
or provisions of this Agreement, and to enforce specifically the performance by such first party under this Agreement, and each party to this Agreement hereby agrees to waive the defense in any
such suit that the other parties to this Agreement have an adequate remedy at law and to interpose no opposition, legal or otherwise, as to the propriety of injunction or specific performance as a remedy, and hereby agrees to waive any requirement
to post any bond in connection with obtaining such relief. The equitable remedies described in this Section 9.11 shall be in addition to, and not in lieu of, any other remedies at law or in equity that the parties to this Agreement may elect to
pursue. 
 9.12. Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES, AND AGREES TO CAUSE ITS
SUBSIDIARIES TO WAIVE, ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

9.13. Governing Law; Venue. THIS AGREEMENT AND THE LEGAL RELATIONS BETWEEN THE PARTIES HERETO SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE CONFLICT OF LAWS RULES THEREOF. THE STATE OR FEDERAL COURTS LOCATED IN THE STATE OF DELAWARE SHALL HAVE EXCLUSIVE JURISDICTION OVER ANY AND ALL DISPUTES BETWEEN THE PARTIES
HERETO, WHETHER IN LAW OR EQUITY, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE AGREEMENTS, INSTRUMENTS AND DOCUMENTS CONTEMPLATED HEREBY AND THE PARTIES CONSENT TO AND AGREE TO SUBMIT TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS. EACH
OF THE PARTIES HEREBY WAIVES AND AGREES NOT TO ASSERT IN ANY SUCH DISPUTE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY CLAIM THAT (I) SUCH PARTY IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF SUCH COURTS, (II) SUCH PARTY AND
SUCH PARTY’S PROPERTY IS IMMUNE FROM ANY LEGAL PROCESS ISSUED BY SUCH COURTS OR (III) ANY LITIGATION OR OTHER PROCEEDING COMMENCED IN SUCH COURTS IS BROUGHT IN AN INCONVENIENT FORUM. THE PARTIES HEREBY AGREE THAT MAILING OF PROCESS OR
OTHER PAPERS IN CONNECTION WITH ANY SUCH ACTION OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 9.2 OR IN SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE THEREOF AND HEREBY WAIVE ANY OBJECTIONS TO SERVICE
ACCOMPLISHED IN THE MANNER HEREIN PROVIDED. 
 [Signature Page Follows] 

 

  
 49 

 IN WITNESS WHEREOF, the parties hereto have executed this Stock Purchase Agreement as of the
date first written above. 
  

			
	ATAI US 2, INC.
		
	By:	 	 /s/ Florian Brand

		 	Name: Florian Brand
		 	Title: President

  

	
	 SELLER:

	
	 /s/ Jonathan Sporn

	 JONATHAN SPORN

 SIGNATURE PAGE 

STOCK PURCHASE AGREEMENTEX-10.8

 Exhibit 10.8 

[***] Certain information in this document has been omitted from this exhibit because it is both 

(i) not material and (ii) would be competitively harmful if publicly disclosed. 

LICENSE AGREEMENT 
 This License Agreement
(the “Agreement”) is entered into on the 14th of August 2017 (“Effective Date”), by and between National University Corporation Chiba University, having an address at
1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263-8522 JAPAN (“Licensor”) and Perception Neurosciences, Inc. having an address at 113 University
Place Suite 1019 New York, New York USA 10003 (the “Company”) (each of Licensor and the Company referred to as a “Party” and collectively as the “Parties”). 

BACKGROUND 
 WHEREAS, Licensor owns
the rights to certain intellectual property rights related to R-ketamine and ketamine metabolites for therapeutic use, including the Licensed Technology further described and defined below; and 

WHEREAS, the Company possesses expertise in the development of therapeutic treatment of human psychiatric disease and wishes to obtain from Licensor,
and Licensor wishes to grant to the Company, an exclusive license with respect to the Licensed Technology in order to manufacture, use and sell Products (as defined below); and 

WHEREAS, Licensor desires to have products and services based on the Licensed Technology developed and commercialized to benefit the public. 

NOW, THEREFORE, in consideration of the promises and covenants contained in this Agreement and intending to be legally bound, the Parties agree as
follows: 
  

	1.	 Definitions 

  

	1.1.	 “Affiliate” means, with respect to either Party, any company, corporation, other entity or
person (hereinafter, collectively, an “Entity”), which is directly or indirectly, controlled by, or controls, or is under common control with such Entity or a holding company of such Entity. For the purposes of this Agreement,
“Control” shall mean the holding, directly or indirectly, of more than 50% (fifty percent) of the issued share capital or capital or of the voting power of the relevant Entity, or the holding, directly or indirectly, of a right to
appoint more than 50% (fifty percent) of the directors of such Entity, or of such other relationship as, in fact, constitutes actual control of such Entity. 

  

	1.2.	 “Company Technology” means existing or future Intellectual Property Right discovered,
generated, invented, licensed or obtained by the Company or on behalf of the Company or any of the employees or consultants or service providers of the Company, including without limitation the Development Results. 

 

	1.3.	 “Development Plan” means the plan for the development and commercialization of Products,
attached hereto as Exhibit A, as may be amended from time to time by the Company in accordance with the provisions hereof. 

  
 1 

	1.4.	 “Development Results” means the results of activities carried out by the Company or by third
parties at the direction of the Company pursuant to the Development Plan or otherwise in fulfillment of the Company’s obligations hereunder, including any invention, patent or patent application, product, material, compound, formula, substance,
method, process, technique, know-how, data, information or other result which do not form part of the Licensed Technology, discovered in the course of, or arising from the performance of the Company’
development work, including any regulatory filing filed, or approval obtained, by the Company, an Affiliate or Sublicensee, as well as any information, material, results, devices and know-how arising
therefrom. 

  

	1.5.	 “FDA” means the United States Food and Drug Administration in the United States or its
successor from time to time. 

  

	1.6.	 “First Commercial Sale” shall mean the first sale of a Product by the company, an Affiliate or
a Sublicensee to an independent and unaffiliated third party in a bona fide arm’s-length transactions after receipt of marketing approval in the country in which such Product is sold. Sales for test
marketing, sampling and promotional uses, clinical trial purposes, compassionate or similar use shall not be considered to constitute a First Commercial Sale. 

 

	1.7.	 “Intellectual Property Rights” means any patents, patent applications, trademarks, trade
names, service marks, domain names, copyrights, data rights, moral rights, rights in and to databases (including rights to prevent the extraction or reutilization of information from a database), design rights, topography rights and all right or
forms of protection of a similar nature or having equivalent or similar effect to any of them which may subsist anywhere in the world, whether or not any of them are registered, and including applications for registration of any of them.

  

	1.8.	 “Know-How” means all and any information, ancillary
materials, results, methods, techniques, processes, compositions, trade secrets, data, know-how, and other information developed and/or owned by the Licensor related to the subject matter claimed in the
Licensed Patents but not including Company Technology. 

  

	1.9.	 “NDA” means a New Drug Application filed with the FDA, as such term is defined by the FDA.

  

	1.10.	 “Net Revenues” means any and all revenue recognized by the Company and its Affiliates and
Sublicensees from: (a) the sale of the Products, less the following: (i) discounts actually given in amounts customary the trade, for distributors, quantity purchases, cash or prompt payments; (ii) credits, or refunds, not exceeding
the original invoice amount, separately and actually granted to customers for Products, as applicable, which are returned to the Company and its Affiliates and Sublicensees; (iii) transportation expenses and transportation insurance premiums,
which are itemized in the invoice, actually paid by the Company and its Affiliates and Sublicensees; (iv) sales taxes (including value added taxes), customs, duties or similar excise taxes and other fees imposed by a government agency to the
extent applicable to such sale and detailed in the invoice in respect of such sale and actually paid by the Company and its Affiliates and Sublicensees (The provision of Products at reasonable quantities for the purpose of clinical trials, beta site
testing or similar uses at no charge shall not be considered to be Net Revenues); and (v) clinical trial costs. 

  
 2 

 With respect to sales by the Company, its Affiliate or Sublicensee, as applicable, to any Affiliate or
Sublicensee, as the case may be, the term “Net Revenues” shall mean the amounts received by such Affiliate or Sublicensee on resale to an independent third party purchaser after deduction of the items specified above, to the extent
applicable. 
  

	1.11.	 “Licensed Patents” means the existing patent applications listed in Exhibit B,
to this Agreement, as well as all patent applications that claim priority therefrom; all divisions, continuations, continuations-in-part,
re-examinations, reissues, substitutions, or extensions, including European Supplementary Protection Certificates (“SPCs”), and any and all patents issuing from, and inventions, methods,
processes, conceptions, subject matter, and other patentable subject matter disclosed or claimed in, any and all of the foregoing. 

  

	1.12.	 “Products” means any products and/or services that the development, manufacture or sale of
which, in whole or in part, is covered by a Valid Claim under any of the Licensed Patents. 

  

	1.13.	 “Royalty Period” means with respect to each Product a period the term for which a Valid Claim
remains in effect which would be infringed by the manufacture, use, offer for sale, sale or import of such Product but for the License granted by this Agreement; unless the License is terminated prior thereto pursuant to the provisions hereof, in
which event the Royalty Period shall continue until the effective date of such termination. 

  

	1.14.	 “S-norketamine Technology” means the existing patent applications listed in Exhibit C,
to this Agreement, as well as all patent applications that claim priority therefrom; all divisions, continuations, continuations-in-part,
re-examinations, reissues, substitutions, or extensions, including European Supplementary Protection Certificates (“SPCs”), and any and all patents issuing from, and inventions, methods,
processes, and other patentable subject matter disclosed or claimed in, any and all of the foregoing, concerning psychiatric use of S-norketamine (“S-norketamine Patents”); and means all and any information, ancillary materials,
results, methods, techniques, processes, compositions, trade secrets, data, know-how, and other information developed and/or owned by the Licensor related to the subject matter claimed in the S-norketamine
Patents, prior to the date of the exercise of the Option (as such term is defined below) (“S-norketamine Know-How”). 

 

	1.15.	 “Sublicense” means any right granted or license given by the Company or its Affiliates of any
of its rights under the License, to any third party other than their Affiliates. 

  

	1.16.	 “Sublicensee” means any person or entity granted a Sublicense. 

 

	1.17.	 “Licensed Technology” means the Licensed Patents and the
Know-How. 

  

	1.18.	 “Third Party Royalties” shall mean any amounts paid by the Company, an Affiliate or a
Sublicensee to a third party (other than an Affiliate or Sublicensee) for the right or license to use the technology, patents and/or other Intellectual Property of such third party that the Company requires in order to prevent the infringement of
the intellectual property rights held by such third party as a result of the use or practice of the Licensed Technology; and provided that the royalty to such third party has been established at

  
 3 

	 	
arm’s-length and in good faith, and is set out in a written agreement. In the event of any dispute between the Parties with respect to whether such
license is necessary as stated above, the matter shall be determined by an independent patent counsel appointed by mutual agreement of the Parties within [***] of the request of either Party, who shall act as an expert and not as an arbitrator and
the determination of such independent patent counsel shall be binding upon the Parties. 

  

	1.19.	 “Valid Claim” means a claim of an issued and unexpired Licensed Patent, including those with
an extended term under patent term adjustment, patent term extension or pediatric exclusivity, claiming the use of R-ketamine or, if the Company exercises the Option (as defined in Section 3 below),
S-norketamine, for depression or other indications covered in the patents which would be infringed by the unauthorized development, manufacture, sale, distribution or use of a product in the country of development, manufacture, sale, distribution or
use, which claim has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction (which decision is no longer appealable), and which claim has not been disclaimed, denied or
admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise (including such claim during the term of any statutory or regulatory exclusivity periods that relate back to
or apply to that claim). 

  

	1.20.	 In this Agreement, unless the context otherwise requires: (i) the singular shall include the plural and
vice-versa; (ii) the masculine gender shall include the female gender; (iii) “including” or “includes” shall mean including, without limiting the generality of any description preceding such terms; (iv) the use of the
term “or” shall mean “and/or”; and (v) any reference to the term “sale” shall include the sale, lease, licensing, rental, or other transfer or disposal of any Product (including, any related service).

  

	1.21.	 “Sale/Sold” means the sale, transfer, exchange or other disposition of Products by the
Company, its Affiliate or Sublicensee. Except respecting sales between the Company, its Affiliates and Sublicensee, sales of Products shall be deemed consummated upon the first to occur of: (a) receipt of payment from the purchaser;
(b) delivery of Products to the purchaser or a common carrier at the risk of the purchaser; (c) release of Products from consignment; (d) if deemed sold by commercial use, when first put to such use; or (e) if otherwise
transferred, exchanged or disposed of when such transfer, exchange, or other disposition occurs. Provision of samples shall not be included in Section 1.21. 

 

	1.22.	 “Field of Use” means Human Therapeutics. 

 

	1.23.	 “IND” means an Investigational New Drug Application filed with the FDA with respect to which
reviews for safety are made to assure that research subjects will not be subjected to unreasonable risk. 

  

	2.	 License Grant and Rights to Sub-License 

 

	2.1.	 Subject to the terms and conditions set forth in this Agreement, the Licensor hereby grants to the Company and
its Affiliates, an exclusive, perpetual (unless duly terminated according to the Agreement terms), worldwide, royalty bearing license in the Field with a 

  
 4 

	 	
right to grant sublicenses under the Licensed Technology, for further researching, developing, having developed, manufacturing, having manufactured, using, having used, offering for sale, having
offered for sale, selling, having sold, exporting, having exported, importing, having imported and/or otherwise commercializing Products for the Field of Use (the “License”). At the end of the Royalty Period in a country or
countries as applicable, i.e., the date of expiration, including any extension or renewal, of the last to expire of the Licensed Patents in such country, the Company shall have a fully paid-up, royalty-free,
exclusive, perpetual and irrevocable License for the Field of Use in relation to the Licensed Technology in such country or countries. 

  

	2.2.	 The Company shall be entitled to grant Sublicenses under the License, on terms and conditions not inconsistent
with the terms of this Agreement through multiple tiers upon written notice to the Licensor. The Company expressly understands and agrees that pursuant to the Industrial Technology Enhancement Law of Japan which is similar to the U.S. Bayh-Dole Act,
it is required to provide notification to and obtain approval of the Japanese government with respect to each such tier of Sublicense. The Company shall ensure that any Sublicense shall include terms that make the Sublicense dependent on the
continued existence of this Agreement and that bind the Sublicensee to observe the relevant material terms of this Agreement. 

  

	2.3.	 Licensor retains on behalf of itself the perpetual, royalty-free right and license to practice the Licensed
Technology for research and educational purposes and for fields of use outside of the Field of Use. In addition, the Company expressly understands and agrees that the Japanese government retains rights in the Licensed Technology under those
provisions of the Industrial Technology Enhancement Law of Japan which are similar to the “march-in” provisions of the U.S. Bayh-Dole Act under which the Japanese government may force the Company and
its Affiliates and Sublicensees to (i) offer a royalty-free (sub)license in the Licensed Technology to the Japanese government if the government determines such (sub)license is necessary to meet requirements for public use or (ii) offer a
royalty bearing (sub)license in the Licensed Technology to a responsible third party selected by the government if the government determines the Company or its Affiliates or Sublicensees have not taken, or are not expected to take, within a
reasonable period of time, effective steps to achieve practical application of the Licensed Technology. 

  

	3.	 Option to obtain License for S-norketamine Technology 

 

	3.1.	 Subject to the payment by the Company of an amount of [***] within [***] following the Effective Date, Company
shall have the option to obtain an exclusive, perpetual (unless duly terminated according to the Agreement terms), worldwide, royalty bearing license in the Field of Use with a right to grant sublicenses under the S-norketamine Technology
(“Option”). Such Option shall be exercisable by the Company on its own discretion, upon sending written notice to such effect to the Licensor at any time within [***] following the Effective Date (“Option
Period”). 

  

	3.2.	 In the event that The Company exercises the Option within the Option Period (“Option Exercise
Date”), then subject to the payment of a License fee in the amount of [***] to the Licensor within [***] of such Option exercise: (i) the S-norketamine Technology

  
 5 

	 	
shall automatically fall under and be included in the License granted to the Company pursuant to Section 2.1 above; (ii) the definition of the term “Licensed Technology” as
used in this Agreement shall automatically be expanded to also include S-norketamine Technology; (iii) the definition of the term “Licensed Patents” as used in this Agreement shall automatically be expanded to also include
S-norketamine Patents; and (iv) the definition of the term “Know-How” as used in this Agreement shall automatically be expanded to also include S-norketamine
Know-How. 

  

	3.3.	 During the Option Period, the Licensor shall not enter into any negotiations and/or into any transaction with
any third party relating to the grant of a license and/or the grant and/or transfer of any rights of any kind, in and/or to the S-norketamine Technology and/or otherwise assign, pledge, transfer and/or dispose of the S-norketamine Technology,
without the Company’s prior written consent. 

  

	3.4.	 In the event that the Company fails to exercise the Option within the Option Period; or the Company notifies
Licensor that it does not wish to exercise such Option, then the Company’s rights under this Section 3 shall lapse and Licensor shall be free to grant license under the S-norketamine Technology to any third party and/or otherwise transfer
and/or dispose of the S-norketamine Technology. 

  

	4.	 Title; No Implied License. 

 

	4.1.	 As between the Parties, all rights, title and interest in and to the Licensed Technology shall be owned solely
and exclusively by Licensor. The license and right granted in this Agreement shall not be construed to confer any rights upon the Company or its Affiliates or Sublicensees by implication, estoppel or otherwise as to any technology not specifically
identified in this Agreement as “Licensed Technology.” 

  

	4.2.	 As between the Parties, all rights, title and interest in and to the Company Technology, shall be owned solely
and exclusively by the Company. 

  

	5.	 Development and Diligence 

 

	5.1.	 The Company shall use reasonable commercial efforts to develop the Product(s) in accordance with the
Development Plan which describes a proposed preclinical and clinical development plan extending [***] from the Effective Date showing the activities planned to advance the Licensed Products, as may be amended by the Company from time to time,
subject to the provisions of section 5.2 below, to introduce the Product to as extensive a market in major countries as is reasonably possible and as soon as reasonably practical, to market, sell, support, service, license, sub-license and otherwise create income and value for the Company, all consistent with sound and reasonable business practices and judgment in the pharmaceutical industry in general, and the Company’s business
discretion as may be modified by Company from time to time. 

  

	5.2.	 The Company shall be entitled, from time to time, to make such adjustments to the Development Plan as the
Company believes, in its good faith judgment, are needed in order to improve the Company’s ability to commercialize the Products(s). The Company shall notify Licensor promptly regarding material changes to the Development Plan, which shall
detail the reasons thereof. 

  
 6 

	5.3.	 Possibility of Selecting Licensor as ARO. If and when the efforts to develop the Product(s) contemplated
in Section 5.1 result in the determination by the Company or its Affiliates or Sublicensees that clinical development in Japan is necessary and appropriate, and either a CRO or ARO is to be selected to act for the Company or its Affiliates or
Sublicensees in connection with such clinical development effort, the Company or its Affiliates or Sublicensees shall consider Licensor as a possible candidate for such ARO to perform the tasks required, provided that, Licensor’s proposal
submitted at the time is within the level of distinction that the Company or its Affiliates or Sublicensees must insist upon such CRO or ARO in terms of the overall capability, including the amount of personnel and time budgeted and planned for each
phase of clinical development in Japan. 

  

	6.	 Confidentiality; Limited Use of Names; 

 

	6.1.	 Confidential information means any information, documents or other written materials for which the Company or
the Licensor, as the case may be (the “Disclosing Party”) identifies and marks as confidential or proprietary at the time it is delivered to the other Party (the “Receiving Party”). Notwithstanding, the Disclosing
Party’s information in tangible form that does not bear any of these legends shall nevertheless be protected hereunder as Confidential Information, if the Receiving Party knew, or should have reasonably known under the circumstances, that the
information was confidential or had been communicated to it in confidence (the “Confidential Information”). 

  

	6.2.	 The Licensed Technology shall be deemed as Confidential Information of the Licensor. The Company Technology
shall be deemed as the Confidential Information of the Company. 

  

	6.3.	 The Receiving Party shall maintain in strict confidence and not disclose to any third party any Confidential
Information of the Disclosing Party and shall not use any Confidential Information except for the purposes of the performance of this Agreement (this includes but is not limited to the Company’s actions and activities in general for the
commercialization of the Licensed Technology and for the development and sale of the Products) and except when such disclosure is legally required. The Receiving Party shall ensure that its employees, consultants, contractors and agents have access
to Confidential Information of the Disclosing Party only on a need-to-know basis and are bound by an obligation of confidentiality and restriction of use similar to the
terms hereof. The foregoing obligation shall not apply to information which the Receiving Party can prove: 

  

	 	6.3.1	 was disclosed to the Receiving Party by a third party that had a right to make such disclosure; or

  

	 	6.3.2	 was known to the Receiving Party prior to the time of disclosure or independently developed by the Receiving
Party, in each case, to the extent evidenced by written records; or 

  
 7 

	 	6.3.3	 became part of the public domain as a result of rightful acts by any person or entity other than the Receiving
Party. 

 Furthermore, a disclosure by Receiving Party of Confidential Information in response to a valid order by a court
or other governmental body, or as otherwise required by law, and to such extent necessary, shall not be considered to be a breach of this Agreement, provided, however, that Receiving Party shall provide the Disclosing Party with prompt prior written
notice thereof to enable the Disclosing Party to seek a protective order or otherwise prevent or contest such disclosure. 
  

	6.4.	 Notwithstanding the foregoing, the Company may disclose to its Affiliates, potential investors, shareholders,
personnel, contractors, business partners and Sublicensees the Licensor Confidential Information to the extent necessary for the exercise by it of its rights hereunder or in the fulfillment of its obligations hereunder, or in the process of
obtaining financing or strategic alliances for the Company or in the conduct of experiments with co-investigators who are not employed by Company, provided that it shall bind such Affiliates, potential
investors, shareholders, personnel, contractors, business partners and Sublicensees with a similar undertaking of confidentiality in writing. In addition, Company may, to the extent necessary, disclose and use Confidential Information disclosed to
it by the Licensor where the disclosure and use of the Confidential Information may be useful or necessary in connection with the procurement of patent rights or obtaining regulatory authorization or certificate for marketing of a Product in any
country. 

  

	6.5.	 In addition to and without derogating from the foregoing, Company undertakes not to make mention of the names
or trademarks of Licensor, or any variation, adaptation or abbreviation thereof, or any scientists or other employees of Licensor in any manner or for any purpose whatsoever in relation to this Agreement, its subject matter and any matter arising
from this Agreement or otherwise, except: (i) that the Company may mention that the Licensed Technology was developed under the auspices of the Licensor and licensed to the Company for any purposes other than advertising; (ii) when
required by the applicable regulatory or other competent authorities or pursuant to applicable law; (iii) when required in filings made in connection with obtaining an FDA approval for marketing of a Product or an equivalent approval in any
other country; (iv) as may be useful or necessary in connection with the Company’s fulfillment of its obligations hereunder; or (v) within the framework of any due diligence investigation. Any other mention must receive prior written
approval of the Licensor. 

  

	6.6.	 Notwithstanding the provisions above, Company shall not be prevented from mentioning the name of Licensor,
and/or any scientists or other employees of the foregoing (including the investigators) or from disclosing any information if, and to the extent that, such mention or disclosure is to competent authorities for the purposes of obtaining approval or
permission for the exercise of the Licensed Patents or the exercise of any of Company’s rights under the License or otherwise under this Agreement, or in the fulfillment of any legal duty owed to any competent authority. 

  
 8 

	6.7.	 No termination of this Agreement, for whatever reason, shall release the Parties from any of their obligations
under this Section 6 and such obligations shall survive any termination for a period of [***], except in relation to any trade secrets, in which case such obligations shall survive any termination for an indefinite period, provided that they
remain trade secrets. Upon termination of this Agreement for any reason, the Receiving Party shall cease to use any Confidential Information of the Disclosing Party, except for the sole purpose of record keeping or monitoring its compliance with the
terms of this Agreement. 

  

	6.8.	 The Parties acknowledge that a breach of this Section 6 may cause the Disclosing Party extensive and
irreparable harm and damage, and agree that the Disclosing Party shall be entitled to seek injunctive relief to prevent the use or disclosure or threatened use or disclosure of the Confidential Information not authorized by this Agreement, in
addition to any other remedy available to Disclosing Party under applicable law. 

  

	6.9.	 The provisions of this Agreement supersede and shall be substituted for any terms of any prior confidentiality
agreement between the Company and Licensor which are not consistent with this Agreement. 

  

	7.	 Consideration. 

In consideration for the License granted hereunder, the Company shall pay Licensor the following: 

 

	7.1.	 License Fee. Within [***] days of the Effective Date of this Agreement, Company shall pay Licensor a
License fee in the amount of [***] (“License Fee”). 

  

	7.2.	 License Maintenance Fees. In addition, commencing on [***] and each year thereafter on each
anniversary date of this Agreement until the filing with the FDA of a NDA for depression, Company shall pay the Licensor an annual License maintenance fee in the amount of [***] per year (“Annual Maintenance Fee”).

 In the event that the Company exercises the Option and the License is expanded to include the S-norketamine Technology
pursuant to Section 3.2 above, then the Company shall commencing on the [***] and each year thereafter on each anniversary date of the Option Exercise Date until the filing with the FDA of a NDA, Company shall pay the Licensor, in
addition to the Annual Maintenance Fee, an amount of [***] per year. 
  

	7.3.	 Running Royalties. Subject to the terms of this Agreement, during the relevant Royalty Period and
provided that the License is not terminated prior thereto pursuant to the provisions hereof, Company will pay to Licensor the following amounts, based on its and its Affiliates’ and Sublicensees’ worldwide Net Sales of Products:

  

	 	7.3.1	 on Company’s and its Affiliates’ and Sublicensees’ worldwide annual aggregate Net Revenues of up
to and including the first [***] of aggregate Net Sales, Company will pay to Licensor [***] of Net Revenues; 

  

	 	7.3.2	 on Company’s and its Affiliates’ and Sublicensees’ incremental worldwide annual aggregate Net
Revenues of more than [***] but up to and including [***] Company shall pay Licensor a royalty of [***] of Net Revenues; 

  
 9 

	 	7.3.3	 on Company’s and its Affiliates’ and Sublicensees’ incremental worldwide annual aggregate Net
Revenues of more than [***] but up to and including [***]; Company shall pay Licensor a royalty of [***] of Net Revenues; and 

  

	 	7.3.4	 on Company’s and its Affiliates’ and Sublicensees’ incremental worldwide annual aggregate Net
Revenues of more than [***] Company shall pay Licensor a royalty of [***] of Net Revenues. 

  

	7.4.	 Third Party Royalties: If the Company, its Affiliate or Sublicensee makes payment of Third Party
Royalties (and in the case of a Sublicensee, such Third Party Royalties are deducted from the royalties paid to the Company), then the Company shall be entitled to set off such Third Party Royalties against amounts otherwise payable to Licensor as
Royalties pursuant to Section 7.3 above, provided that the amount of such set-off shall not exceed [***] of such Royalties, as applicable. To illustrate, if during the Term and after the First Commercial
Sale of a Licensed Product(s), Company owes a royalty or payment to any person or entity (other than the Licensor) (a “Third Party”): (i) with respect to any technology, know-how, patent
application, patents or other intellectual property used for the development, manufacture, production, use or sale of a Licensed Product; (ii) in order to avoid or settle a claim that any Licensed Product or any portion of the Licensed
Technology infringes any of such Third Party’s intellectual property rights; or (iii) pursuant to a judicial or arbitral decision that finds Company, Affiliate, or any Sublicensee, liable to make such payments in respect of an infringement
claim referred to in (ii) above (collectively, “Third Party Royalties”), then Company shall be entitled to set off the Third Party Royalties against the royalties set forth above due to the Licensor with respect to
Company’s Revenues. However, whatever the circumstances may be, in no case shall the Licensor’s royalty be reduced by more than [***]. 

  

	7.5.	 Milestone Payments. 

  

	 	7.5.1	 In addition, the Company shall with respect to each of the 2 (two) first Products pay Licensor the following
milestone payments following the specified events below with respect to each such Product: 

  

	 	7.5.1.1.	   [***]; 

 

	 	7.5.1.2.	   [***]; 

 

	 	7.5.1.3.	   [***]; and 

 

	 	7.5.1.4.	   [***] 

 

	 	7.5.2	 With respect to each of additional Products (beyond the first 2 (two) Products) Company shall pay Licensor the
following milestone payments following the specified events below with respect to each such Product: [ 

  

	 	7.5.2.1.	   [***]; 

 

	 	7.5.2.2.	   [***]; and 

 

	 	7.5.2.3.	   [***] 

The above milestone payments are non-refundable and
non-creditable. 

  
 10 

	7.6.	 The above Royalties payable pursuant to Section 7.3 are to be paid on [***] basis, for the Net Revenues
actually received by the Company and its Affiliates and Sublicensees during the relevant [***], provided that in the event that this Agreement is terminated for any reason, the final accounting and payment of Royalties due to Licensor shall be made
within [***] of the date of the effective date of termination of the Agreement. 

  

	7.7.	 Within [***] after the end of each [***] during the term of this Agreement, the Company shall deliver to
Licensor true and accurate reports showing such particulars of the business conducted by Company and its Affiliates and Sublicensees during the relevant [***] as is required to calculate the milestone payments set forth in Section 7.5 hereof
and the Royalties due Licensor under Section 7.3 hereof. Such reports shall include at least (a) the status of IND, clinical trials, approval, registration or authorization, and First Commercial Sale, and (b) the quantities of each
Product sold in each relevant country, and (c) Net Revenues generated during the relevant [***], and (e) the Royalties owed to Licensor pursuant to Section 7.3 hereof with respect to the relevant [***]. If no payments are due, the
Company shall so report. If any milestone payments or Royalties are due, together with each such report, subject to the receipt of Licensor’s invoice, the Company will pay the milestone payments and Royalties due to the Licensor respectively.
All reports under this Section shall be considered part of Company’s Confidential Information. 

  

	7.8.	 Any payments to be made under this Agreement that are not paid on or before the date such payments are due
under this Agreement, shall bear annual interest, compounded monthly, at a rate equal to [***], assessed from the day payment was initially due until the date of payment. The payment of such interest shall not foreclose Licensor from exercising any
of other rights it may have because any payment is late. 

  

	7.9.	 The consideration set forth herein, constitutes the sole consideration due to Licensor or any of its personnel
in connection with the grant of the License hereunder or from the development, manufacture or sale of the Products or otherwise from the commercialization of the Licensed Technology hereunder. 

 

	7.10.	 If the Company is required to withhold any amounts payable hereunder to Licensor due to the applicable laws of
any country, such amount will be deducted from the payment to be made by the Company and remitted to the appropriate taxing authority for the benefit of Licensor, unless Licensor provides the Company with a tax certificate from the relevant
authorities indicating a zero tax withholding, in which case all payments shall be made without the withholding of any such applicable taxes. Subject to foregoing, the Company may withhold only such amounts as are required to be withheld by
applicable law in the country from which payment is being made. The Company shall submit to Licensor originals of the remittance voucher and the official receipt evidencing the payment of the corresponding taxes with the applicable royalty report.
The Company will reasonably cooperate with Licensor to provide such information and records as Licensor may require 

  
 11 

	 	
in connection with any application by Licensor to the tax authorities in any country, including attempt to obtain an exemption or a credit for any withholding tax paid in any country.

  

	7.11.	 Any payments to be made to Licensor under this Agreement shall be made upon receipt of itemized invoices which
set forth amounts due under this Agreement. Uncontested amounts due under invoices issued hereunder shall be payable within [***] of the Company’s receipt of invoice (invoices to be sent to the Company at its address below).

  

			
	Invoices shall be sent to:	  	Perception Neurosciences, Inc.
		  	ATTN: [***]
		  	113 University Place Suite 1019
	 	  	New York, New York USA 10003

  

	7.12.	 Any payments to be made to Licensor under this Agreement shall be paid in US Dollars and by telegraphic
transfer to the bank account(s) which Licensor shall designate in its invoices for the fees, payments and royalties owed to Licensor hereunder. For the avoidance of doubt, any amounts payable to Licensor under this Agreement shall, except to the
extent withheld pursuant to Section 7.10 hereof, be net receivable to Licensor, i.e., not subject to any bank charges of the banks of Licensor involved in the telegraphic transfer. For sales which take place outside of the US and its
territories, the rate of exchange between local currency and US Dollars applicable to the royalty obligation of the Company shall be the TTS rate published by a first-class bank for the close of business in New York, New York on the last day of the
calendar year for which the royalty payments are being made. 

  

	8.	 Reports; Records and Audit 

 

	8.1.	 The Company shall inform Licensor in writing of the date of each First Commercial Sale with respect to each
Product in each country, as soon as practicable after the making of each such commercial sale. 

  

	8.2.	 The Company shall maintain, and shall use commercially reasonable efforts to ensure that its Affiliates and
Sublicensees maintain, complete and accurate records of Products that are made, used, marketed, offered for sale or sold under this Agreement, and any amounts payable under this Agreement in relation to such Products, which records shall be in such
form and manner that all milestone payments and Royalties owed hereunder to Licensor may be readily and accurately determined and shall not only contain all information necessary for the Company’s CPA to prepare the reports required by
Section 7.7 of this Agreement but also contain sufficient information to permit Licensor to confirm the accuracy of any reports or notifications delivered under this Agreement. The Company shall be required to retain the aforesaid records at
all times during the term of this Agreement and for a period of [***] after termination of this Agreement. 

  

	8.3.	 Licensor shall have the right, at its expense (subject to the second last sentence below), exercisable not more
than [***] every year, to cause a certified, independent public accountant selected by Licensor and reasonably acceptable to the Company 

  
 12 

	 	
(“Independent Public Accountant”), upon reasonable prior notice, to inspect and audit such records for the sole purpose of verifying any reports and payments delivered under this
Agreement. 

 Such Independent Public Accountant shall not disclose to Licensor any information other than information relating
to the accuracy of reports and payments delivered under this Agreement, or to the existence and content of any agreements, contracts or arrangements which are not in accordance with the Agreement. The Company shall be entitled to receive a
copy of the final report of such Independent Public Accountant of the results of the audit, if Licensor notifies the Company that the audit revealed an underpayment or overpayment. 

The Parties shall reconcile any underpayment within [***] after the Independent Public Accountant delivers the results of the audit and such
results are confirmed by the Company’s CPA. In the event that any audit performed under this Section reveals an underpayment in excess of [***] in any calendar year, Company shall bear the reasonable cost of such audit. For purposes of the
aforesaid audit, the Company shall only be required to provide information that is directly relevant to such audit, and any such audit must be conducted during regular working hours of the Company. Such audit shall be conditioned upon execution of a
standard nondisclosure agreement. Any overpayment shall be credited against future Royalties or other payments to be made by the Company to the Licensor hereunder. If such overpayment is revealed after the Company’s obligation to pay Royalties
or other payments hereunder has ceased, the Licensor shall pay the amount of such overpayment to the Company within the said [***] period referred to above. 
  

	9.	 Term and Termination 

 

	9.1.	 This Agreement shall come into effect upon the Effective Date and unless earlier terminated as provided in this
Section 9, shall continue, in full force and effect until the expiration on a country by country basis or abandonment, including any extension or renewal, of the last valid Licensed Patent in such country. Upon any such expiration of this
Agreement, the Company shall have a fully paid-up, royalty-free, non-exclusive, perpetual and irrevocable license in relation to the
Know-How. 

  

	9.2.	 Unless otherwise specifically provided in this Agreement, in the event that either Party breaches its
undertakings under this Agreement and does not cure the breach within [***] after written notice of the breach (which notice shall include reference to the non-breaching Party’s intention to terminate
this Agreement if breach is not cured), this Agreement shall automatically terminate on this account. Such period shall be extended, if necessary, to take into account any delay or cessation of activities caused by a delay or deviation attributed to
Licensor, or Force Majeure in accordance with Section 13.9 below. Such notice and termination shall not prejudice the non-breaching Party’s rights to any sums due hereunder before termination and
shall not prejudice any cause of action or claim of the non-breaching Party accrued or to accrue on account of the breach. The failure of the Company or its Affiliates or Sublicensees to develop and market the
Product(s) in one or more countries shall not constitute a breach of this Agreement provided the obligation of commercial reasonable efforts to develop and market as set forth in Section 5.1 hereof, have been or are being met.

  
 13 

	9.3.	 Without prejudice to the generality of the foregoing, Licensor shall be entitled to terminate the Agreement
upon [***] written notice, at any time after the occurrence of any of the following events with respect to the Company (unless such event ceases within such period): (i) insolvency, bankruptcy or liquidation or filing of any application therefor, or
other commitment of an affirmative act of insolvency which is not dismissed or withdrawn within [***]; (ii) attachment, execution or seizure of substantially all of the assets or filing of any application therefor which is not dismissed within
[***]. Such notice and termination shall not prejudice Licensor’s rights to any milestone payments, Royalties, and other sums due hereunder before termination and shall not prejudice any cause of action or claim of Licensor accrued or to accrue
on account of the aforesaid events with respect to the Company. 

  

	9.4.	 In addition to the foregoing, the Company will have the right at any time and for any reason whatsoever to
terminate this Agreement upon a prior written notice to Licensor of ninety (90) days. Such termination shall not relieve the Company from any obligations which may be due and outstanding as of immediately prior to the termination date.

  

	9.5.	 Upon termination of this Agreement pursuant to this Section 9, other than due to the expiration of its
term: 

  

	 	9.5.1	 the rights and licenses granted to and by the Company under Section 2 shall terminate with respect to
Licensed Technology that falls under Valid Patent. In the event of the termination or expiration of this Agreement, all financial obligations of the Company toward Licensor hereunder, shall terminate, other than any of Company’s outstanding
obligations prior to the termination date; 

  

	 	9.5.2	 The Company or its Affiliates or Sublicensees may continue to sell in the ordinary course of business
reasonable quantities of Products which are fully manufactured and in the Company’s or its Affiliates’ or Sublicensees’ normal inventory at the date of termination if (a) all monetary obligations of the Company to Licensor have
been satisfied and (b) Royalties on such sales are paid to Licensor in the amounts and in the manner provided in this Agreement, but shall thereafter have no license under the Licensed Technology. 

 

	9.6.	 The provisions of Sections 1, 4, 6, 7.8 - 7.10, 8, 9.1, 9.5, 10.1, 12 and 13 shall survive any termination or
expiration of this Agreement. 

  

	10.	 Patent Filing, Prosecution and Maintenance 

 

	10.1.	 [***] 

  

	10.2.	 For the avoidance of doubt, the filing, prosecution, enforcement, defense and maintenance of patents covering
the Company Technology shall be made by the Company and registered in the name of the Company and any inventor thereunder at the Company’s expense. 

  
 14 

	10.3.	 Following the date of execution of this Agreement, the Company [***] and in consultation with Licensor,
shall be responsible for the filing, prosecution and maintenance of the Licensed Patents, through outside patent counsel selected by the Company and reasonably acceptable to Licensor. Each application and every patent registration shall be made and
registered in the name of Licensor or, should the law of the relevant jurisdiction so require, in the name of the relevant inventors and then assigned to Licensor. Licensor shall be afforded opportunities to advise the Company and the outside patent
counsel and shall cooperate with Company in such filing, prosecution and maintenance. The Company shall require the outside patent counsel engaged by the Company as aforesaid to deliver in a timely manner to Licensor copies of all communications
received from any patent office or foreign associate patent counsel, as well as copies of drafts of communications and/or applications, for review by Licensor and shall further require such outside patent counsel to reasonably consider any comments
of Licensor with respect to such drafts. 

  

	10.4.	 Notwithstanding, in the event that the Company should decide to cease prosecution and/or maintenance of any
patent application(s) or patent(s) within the Licensed Patents in any country, the Company shall notify Licensor in writing and the Licensed Patents shall thereafter exclude such patent application(s) or patent(s) in such country, and the Company
shall have no further rights under the Licensed Patents in such country and [***]. The Company shall be entitled to exercise the right and license hereunder with respect to the Licensed Technology, other than the patent(s) or application(s)
removed therefrom as aforesaid, in such country, subject to the payment of Royalties and other payments pursuant to Section 7 above. 

  

	10.5.	 The Parties shall assist each other in all respects relating to the preparation of documents for the
registration of any patent or any patent-related right within the Licensed Patents upon the request of the other Party. The Parties shall take all appropriate action in order to assist each other to extend the duration of any patent within the
Licensed Patents or obtain any other extension obtainable under law, to maximize the scope of the protection afforded by the Licensed Patents. 

  

	11.	 Infringement and Litigation 

 

	11.1.	 The Parties are responsible for notifying each other promptly of any infringement of the Licensed Technology
that may come to their attention. The Parties shall consult one another in a timely manner concerning any appropriate response to the infringement. 

  

	11.2.	 The Company shall have the first right, but not the obligation, to take action in the prosecution, prevention,
or termination of any infringement and control the prosecution of such infringement at its sole discretion and [***]. The Company shall not settle any such suit in a manner that imposes any obligations or restrictions on the Licensor or
compromises the Licensed Technology, without the prior written permission of the Licensor, which shall not be unreasonably withheld, delayed or conditioned. Whenever any suit is brought against any infringer by the Company as above provided, the
Company shall immediately notify the Licensor of such suit. 

  
 15 

	11.3.	 If the Company elects not to file any claim or suit for infringement of the Licensed Technology, Licensor may,
[***], elect to do so by written notice to Company. In addition, Licensor shall, if so required by the law of the forum, join the Company (including as plaintiff or co-plaintiff) in any claim or suit
for infringement of the Licensed Technology, [***]. For this purpose the Licensor shall execute such legal papers as may be necessary for the prosecution of such suit and requested by the Company and shall provide all other necessary
assistance. 

  

	11.4.	 The Company shall [***]. 

 

	11.5.	 Subject to the aforementioned obligations, in any action to enforce the Licensed Technology, either Party, at
the request and expense of the other Party shall cooperate to the fullest extent reasonably possible. This provision shall not be construed to require either Party to undertake any activities, including legal discovery, at the request of any third
party except as may be required by lawful process of a court of competent jurisdiction. 

  

	12.	 Warranties; Indemnification; Insurance; Liability 

 

	12.1.	 Licensor represents and warrants that it has the full legal right and authority to enter into this Agreement
and to grant the right and license set forth in Section 2 above to the Company. Licensor further represents and warrants that: (i) it has not and will not grant, license, convey, assign, and/or transfer to any third party any rights,
inconsistent with the right and license set forth in Section 2 above and other rights granted hereunder; (ii) it has not received any notice of any legal claims, demands, threats or proceeding of any kind by any third party against it
contesting the ownership or validity of the Licensed Technology, or claiming that the practice of the Licensed Technology in the manner contemplated by this Agreement would infringe the rights of such third party; and undertakes to promptly notify
the Company of any such claim, suit or proceeding of which it becomes aware. 

  

	12.2.	 The Company shall defend, indemnify and hold harmless the Licensor, its Affiliates, trustees, officers,
directors, researchers, agents and employees (individually, an “Indemnified Party”, and collectively, the “Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense which
the Indemnified Parties shall be required to suffer, pay or incur to any third party (including reasonable out-of-pocket investigative costs, court costs and reasonable
attorney’s fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of or is alleged to result from or arise out of : (a) the development, use,
manufacture, promotion, sale or other disposition of the Licensed Technology or the Products, by the Company or any of its Affiliates or Sublicensees, whether asserted under a tort or contractual theory or any other legal theory, unless they are
caused due to Indemnified Party’s negligence or willful misconduct solely in connection with its performance or non-performance of this Agreement and/or any terms thereof 

 

	12.3.	 Licensor shall inform the Company promptly following any receipt of notice of any claim or action giving rise
to Liabilities and shall allow the Company control of the defense of the same or represent the interests of the Indemnified Party in respect of such claim, that shall include the right to select and direct legal counsel and other consultants to
appear in proceedings on behalf of the Indemnified Party and to propose, accept or reject offers of settlement, provided however that the Company is not permitted to settle or compromise

  
 16 

	 	
any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on the Indemnified Parties without prior written consent of the Licensor, which shall not
be unreasonably withheld or delayed. Licensor shall cooperate with the Company regarding the response to and the defense of any such claim. The Indemnified Party/ies shall not settle any claim without the prior written consent of the Company.
Nothing herein will prevent each Indemnitee from retaining its own counsel and participating in its own defense at its own cost and expense. If the Company fails or declines to assume the defense of any such claim or action within [***] after
notice thereof, Licensor may assume the defense of such claim or action at the risk of Company, and any Liabilities related thereto and reasonably incurred by Licensor shall be conclusively deemed a liability of the Company. 

 

	12.4.	 Insurance 

  

	 	12.4.1	 The Company shall maintain insurance that is reasonably adequate to fulfill any potential obligation to the
Indemnitees under this Section 12, taking into consideration, among other things, the nature of the products or services commercialized. Without limiting the foregoing, commencing at the time any Licensed Product is being commercially
distributed or sold, such insurance shall include commercial liability insurance in amounts standard in the industry. During clinical trials of any such Licensed Product, the Company shall, at its sole cost, procure and maintain a clinical trial
insurance policy consistent with industry standards in such amounts as required by the applicable regulatory authority. Such insurance shall be obtained from a reputable insurance company. 

 

	 	12.4.2	 Licensor shall be added as a co-insured party under such insurance
policy. The policy or policies so issued shall include a “cross-liability” provision pursuant to which the insurance is deemed to be separate insurance for each insured (without right of subrogation as against any of the insured under the
policy, or any of their representatives, employees, officers, directors or anyone in their name) and shall further provide that the insurer will be obliged to notify each insured in writing at least [***] in advance of the expiry or
cancellation of the policy or policies. The Company hereby undertakes to comply punctually with all obligations imposed upon it under such policy or policies and in particular, without limiting the generality of the foregoing, to pay in full and
punctually all premiums and other payments for which it is liable pursuant to such policy or policies. 

  

	12.5.	 NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY LICENSOR THAT ANY
PATENT WILL ISSUE BASED UPON ANY PENDING APPLICATION INCLUDED IN THE LICENSED PATENTS, THAT ANY PATENT INCLUDED IN THE LICENSED PATENTS WHICH ISSUES WILL BE VALID, OR THAT THE USE OF ANY LICENSED PATENTS WILL NOT INFRINGE THE PATENT OR PROPRIETARY
RIGHTS OF ANY OTHER PERSON. EXCEPT FOR BREACH OF SECTION 6 ABOVE, IN NO EVENT SHALL THE COMPANY OR LICENSOR, OR ANY OF THEIR RESPECTIVE AFFILIATES, TRUSTEES, SHAREHOLDERS, DIRECTORS, OFFICERS, RESEARCHERS, AGENTS OR EMPLOYEES, BE LIABLE TO THE

  
 17 

	 	
OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING LOSS OF PROFITS, REVENUE, DATA, OR USE), INCURRED BY COMPANY OR THE LICENSOR OR ANYBODY ON THEIR BEHALF, AS
THE CASE MAY BE, OR BY ANY THIRD PARTY WHETHER IN AN ACTION IN CONTRACT OR TORT, EVEN IF THE COMPANY OR LICENSOR, AS THE CASE MAY BE, OR ANY OTHER PERSON HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

 

	13.	 Additional Provisions 

 

	13.1.	 Nothing in this Agreement shall be deemed to establish a relationship of principal and agent between licensor
and the Company, nor any of their agents or employees for any purpose whatsoever, nor shall this Agreement be construed as creating any other form of legal association or arrangement that would impose liability upon one party for the act or failure
to act of the other party. 

  

	13.2.	 Neither Party shall assign any of its rights nor obligations under this Agreement without the prior written
consent of the other Party, such consent not to be unreasonably withheld; provided, however, that Company may assign or otherwise transfer its rights and obligations to an Affiliate or as part of a transaction resulting in a merger or acquisition,
reverse merger, change of control, asset transfer, where all of the assets of related to the subject matter of this Agreement are sold, transferred and/or assigned to a third party, without consent of Licensor. Subject to the foregoing, this
Agreement shall be fully assumed by and inure to the benefit of the Party’s respective successors and permitted assignees. 

  

	13.3.	 A waiver by either Party of a breach of any provision of this Agreement shall not constitute a waiver of any
subsequent breach of that provision or a waiver of any breach of any other provision of this Agreement. 

  

	13.4.	 Notices, payments, statements, reports and other communications under this Agreement shall be in writing and
shall be deemed to have been received (i) upon personal delivery; (ii) [***] after the date of facsimile of electronic transmission (with written non-automated confirmation of receipt); or (iii)
[***] after deposit for prepaid delivery by a reputed international overnight courier service, return receipt requested, if sent to the following addresses, unless the Parties are subsequently notified of any change of address in accordance
with this Section 13.4: 

 It is also understood that any notice herein required or permitted to be given may be
given, in addition to the manner set for the above, by e-mail, provided that the Party giving such notice obtains non-automated acknowledgment by e-mail that such notice has been received by the Party to be notified. Notice made in this manner shall be deemed to have been given when such acknowledgment has been transmitted. 

  
 18 

 If to Licensor at: 

National University Corporation Chiba University 

8-1 Inohana 1-chome, Chuo-ku, Chiba-shi, Chiba 260-8677 
 JAPAN 

Attention: [***] 

Telephone:    [***] 

Facsimile:     [***] 

Email: [***] 

If to Company at:     

Perception Neurosciences, Inc. 

113 University Place Suite 1019 

New York, New York 10003 

USA 

Attention: [***] 

Telephone: 

Facsimile: 

Email: [***] 

with copies to (which shall not constitute notice): 

[***] 

Pearl Cohen Zedek Latzer Baratz LLP 

1500 Broadway 

New York, New York 10036 

USA 

Telephone:    [***] 

Facsimile:     [***] 

Email: [***] 
  

	13.5.	 This Agreement shall be construed and governed in accordance with the laws of the State of New York, USA,
without giving effect to conflicts of law provisions. In the event that a dispute relating to and/or resulting from this Agreement, the Parties will, as soon as practicable, confer in an attempt to resolve the dispute. In the event of a dispute that
cannot be resolved amicably between the Parties within [***] from the date on which the first notice regarding such dispute was sent by one of the parties to the other Party or such longer period as the Parties mutually agree in writing, the dispute
shall be brought in a court of competent jurisdiction in Tokyo, Japan, and the Parties hereby irrevocably consent to the exclusive jurisdiction of the courts sitting in Tokyo, Japan. 

 

	13.6.	 If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, then such illegality,
invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal,
invalid or unenforceable provision were not contained herein. 

  

	13.7.	 Each Party shall bear its own expenses in connection with the negotiation of execution of this Agreement.

  
 19 

	13.8.	 This Agreement (including its Exhibits) embodies the entire agreement and understanding among the Parties
hereto and thereto and supersedes all prior agreements and understandings relating to the subject matter and any and all such previous agreements and understanding are hereby terminated and void. This Agreement may not be changed, modified, extended
or terminated except by written amendment executed by an authorized representative of each Party. 

  

	13.9.	 Neither Party will be responsible for delays to the extent, and for so long as, such failure or delay results
from causes beyond the reasonable control of such Party, and without fault of such Party, including, without limitation, fire, explosion, embargoes, wars, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes,
lockouts or other labor disturbances, acts of God, or acts, omissions or delays in acting by any governmental authority (“Force Majeure”), provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove
such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. The non-performing Party shall promptly notify the other Party in writing
when such circumstances cause a delay or failure in performance and when they cease to do so. 

 IN WITNESS WHEREOF, the Parties,
intending to be legally bound, have caused this Agreement to be executed by their duly authorized representatives. 
  

									
	 Perception Neurosciences, Inc.
	 		  	 National University Corporation Chiba University

					
	Signature:	 	 /s/ [***]
	 	 

        
	  	Signature:	  	 /s/ [***]

	Name:	 	[***]	 		  	Name:	  	[***]
	Title:	 	President and CEO	 		  	Title:	  	Obligating Officer, Administration Bureau
	Date:	 	 August 14, 2017
	 		  	Date:	  	 July 25, 2017

  
 20 

 [***] Certain information in this document has been omitted from this exhibit because it is
both 
 (i) not material and (ii) would be competitively harmful if publicly disclosed. 

AMENDMENT NO.1 
 to

 LICENSE AGREEMENT 
 This Amendment
No.1 to the License Agreement dated August 14, 2017 (the “Original Agreement”) by and between National University Corporation Chiba University, having an address at 1-33 Yayoi-cho,
Inage-ku, Chiba-shi, Chiba 263-8522 JAPAN (“Licensor”) and Perception Neurosciences, Inc. having an address at 113 University Place Suite 1019 New York, New York USA 10003 (the
“Company”) is entered into on 7th of August 2018, by and between Licensor and Company. 
 BACKGROUND 

WHEREAS, the Parties hereto executed the Original Agreement on August 14, 2017 and the Parties hereto now desire to execute this Amendment No.1
for the purpose of supplementing and amending such Original Agreement. 
 NOW, THEREFORE, in consideration of the promises and covenants contained in
this Agreement and intending to be legally bound, the Parties agree as follows: 
  

	A.	 Defined Terms 

Except as otherwise provided herein, capitalized tents used in this Amendment No.1 shall have the meanings given in the Original Agreement. 

 

	B.	 Amendments 

(A) S-norketamine Option Period. Wherein the Option Period for the S-norketamine Technology set forth in section 3.1 expires on [***], the Parties wish
to continue and extend said Option Period for an additional period of [***], beginning with the expiration of the original Option Period and expiring on [***]. Section 3.1, as amended, shall read in its entirety as follows: 

“Subject to the payment by the Company of an amount of [***] within [***] following the Effective Date, Company shall have the option to obtain an
exclusive, perpetual (unless duly terminated according to the Agreement terms), worldwide, royalty bearing license in the Field of Use with a right to grant sublicenses under the S-norketamine Technology
(“Option”). Such Option shall be exercisable by the Company on its own discretion, upon sending written notice to such effect to the Licensor at any time within the first eighteen months following the Effective Date (“Option
Period”).” 
  

	C.	 Effect of Amendments 

This Amendment No.1 shall become effective upon execution. 
 Upon
effectuation of this Amendment No.1, the Original Agreement shall be deemed to include the amendments made hereby and the Original Agreement as amended by Amendment No.1 shall be deemed to constitute one instrument. 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Amendment No.1 to be
executed by their duly authorized representatives. 
  

									
	 Perception Neurosciences, Inc.
	 		  	 National University Corporation Chiba University

					
	Signature:	 	 /s/ [***]
	 	 

        
	  	Signature:	  	 /s/ [***]

	Name:	 	[***]	 		  	Name:	  	[***]
	Title:	 	President and CEO	 		  	Title:	  	Obligating Officer, Administration Bureau
	Date:	 	 August 8, 2018
	 		  	Date:	  	 August 27, 2018

  
 2 

 [***] Certain information in this document has been omitted from this exhibit because it is both
(i) not material and (ii) would be competitively harmful if publicly disclosed. 
 SECOND AMENDMENT TO LICENSE AGREEMENT

 THIS SECOND AMENDMENT TO THE LICENSE AGREEMENT (“Second Amendment”) is made and entered into as of
March 17, 2020 (the “Second Amendment Date”), by and between Perception Neurosciences, Inc., having an address at 113 University Place, Suite 1019, New York, New York USA 10003 (“Company”) and
National University Corporation Chiba University, having an address at 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 263-8522 Japan (“Licensor”).
Each of Licensor and Company may be referred to herein as a “Party” or collectively as the “Parties.” 

WHEREAS, Licensor Licensor and Company are parties to that certain License Agreement, dated August 14, 2017 (the “License
Agreement”) and certain Amendment No. 1, dated August 7th, 2018, pursuant to which, among other things, Licensor granted Company an exclusive license exploit certain patents and know-how as human
therapeutics and an option to obtain an exclusive license to certain S-norketamine technology; 
 WHEREAS, the Company timely
exercised its option to obtain an exclusive license to certain S-norketamine technology; and 
 WHEREAS, the Parties wish to
amend the License Agreement to (a) set forth their mutual understanding with respect to the optioned S-norketamine technology and (b) include additional patents in the License (as defined in the License Agreement). 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises herein made and exchanged, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

1.    Defined Terms. Capitalized terms used but not otherwise defined in this Amendment shall have the
meanings provided in the License Agreement. 
 2.    Option Exercise. The Parties hereby acknowledge that:
(a) in February 2019, Company timely exercised its Option pursuant to Section 3.1 of the License Agreement; (b) paid Licensor an option exercise fee of [***] pursuant to Section 3.2 of the License Agreement; and (c) as a
result of sub-clause (a) and (b), the S-norketamine Technology was automatically included in the License granted to Company pursuant to Section 2.1 of the License Agreement. 

3.    Amendment of Exhibit B. Effective as of the Amendment Date, Exhibit B of the License Agreement is
hereby replaced with Exhibit B attached hereto. 
 4.    Amendment of Article 7 (Consideration). Effective
as of the Amendment Date, Article 7 is hereby amended by adding the following text to the end of Article 7 as follows: 
  

	 	“7.13	 In partial consideration for the additional patent rights granted to Company by Licensor pursuant to that
certain Second Amendment to License Agreement by and between the Parties dated March 17, 2020 (such patents “Additional Patents” and such agreement the “Second Amendment”), within [***] of the
effective date of the Second Amendment, Company shall pay Licensor a license fee of [***]. 

	 	7.14	 In partial consideration for the Additional Patent rights granted to Company by Licensor pursuant to the Second
Amendment, in addition to those fees set forth in Sections 7.2, commencing on [***] and each year thereafter on each anniversary date of the Second Amendment until the filing with the FDA of a NDA in any indication, Company shall pay Licensor an
annual maintenance fee in the amount of [***]. 

 5.    Amendment of Article 10 (Patent
Filing, Prosecution and Maintenance). Effective as of the Amendment Date, Section 10.1 is hereby amended by adding the following text to the end of Section 10.1 as follows: 

“[***]” 
  

	 	6.	 MISCELLANEOUS. 

(a)    Effect of Amendment. The provisions of the License Agreement are hereby amended by the provisions of
this Second Amendment. Except as expressly amended by this Second Amendment, the License Agreement shall remain in full force and effect in accordance with its terms. 

(b)    Counterparts. This Second Amendment may be executed in counterparts, each of which shall be deemed an
original document, and all of which, together with this writing, shall be deemed one instrument. This Second Amendment may be executed by electronic, facsimile or PDF signatures, which signatures shall have the same force and effect as original
signatures. 
 Signature Page to Follow 

  
 2 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this
Amendment to be executed by their duly authorized representatives. 
  

									
	Perception Neurosciences, Inc.	 	        	 	National University Corporation Chiba University
					
	By:	 	 /s/ [***]
	 		 	By:	 	 /s/ [***]

	Name:	 	[***]	 		 	Name:	 	[***]
	Title:	 	Chief Executive Officer	 		 	Title:	 	Obligating Officer, Administration Bureau

  
 3 

 [***] Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDMENT NO. 3 TO LICENSE AGREEMENT

 This AMENDMENT NO. 3 (this “Amendment”) to that certain LICENSE AGREEMENT, dated as of August 14,
2017 and amended on August 7, 2018 and March 17, 2020 (the “License Agreement”), is made and entered into effective as of March 5, 2021, between Perception Neurosciences, Inc., a company organized and existing under
the laws of Delaware, having an address at 180 Varick Street, Suite 637, New York, NY 10014, USA (“Company”) and National University Corporation Chiba University, having an address at 1-33 Yayoi-cho, Inage-ku Chiba-shi, Chiba 263-8522 (“Licensor”) (Company and
Licensor are referred to herein individually as a “Party” and collectively as the “Parties. 
 RECITALS

 WHEREAS, Licensor and Company have entered into that certain License Agreement pursuant to which Company received a license to
certain intellectual property rights owned by Licensor and related to R-ketamine and ketamine metabolites for therapeutic use; and 

WHEREAS, Licensor and Company now desire to amend the License Agreement. 

NOW, THEREFORE, in consideration of the following mutual covenants contained herein, the Parties agree as follows: 

 

	1.	 Definitions. Capitalized terms used but not otherwise defined in this Amendment have the meanings
provided in the License Agreement. 

  

	2.	 Amendment to the definition of “Net Revenues”. Clause (iv) of Section 1.10 of the
License Agreement is hereby amended and restated in its entirety as follows: 

 (iv) sales taxes (including value added
taxes), customs, duties or similar excise taxes and other fees imposed by a government agency to the extent applicable to such sale and detailed in the invoice in respect of such sale and actually paid by Seller; 

 

	3.	 Amendment to the definition of “Net Revenues”. Section 1.10 of the License Agreement is
hereby amended by adding the following clause: 

 and (vi) any other deductions that are consistent with IFRS or GAAP,
but that are not be duplicative of the above deductions. 
  

	4.	 Amendment to the definition of “Net Revenues”. Section 1.10 of the License
Agreement is hereby amended by adding the following paragraphs to the end of Section 1.10: 

 Notwithstanding the
above, the following shall not be included in the computation of Net Revenues: (i) sales between or among the Company, Affiliates and its Sublicensees (each, a “Seller”) (but Net Revenues shall include sales to the first Third
Party (other than a Sublicensee) by Seller); or (ii) the sale, distribution or supply of Product (A) as promotional or other samples, for use in non-clinical studies or clinical studies, or for use
in any test or studies reasonably necessary to comply with any applicable laws or as is otherwise normal and customary in the industry; or (B) for compassionate use, named-patient use, or expanded access, indigent or other patient access
programs if sold at or below the fully burdened manufacturing cost thereof. 

 All such discounts, allowances, credits, rebates, and other deductions shall be fairly and
equitably allocated to any Product and other products of such Seller such that any Product does not bear a disproportionate portion of such deductions. 

If a Seller sells a Product in a country as part of a therapy or product in combination with other pharmaceutical or biologic products,
diagnostic products, ingredients, delivery devices or other components other than R-ketamine (each, an “Other Product”) whether combined in a single formulation or package, formulated or
packaged separately but sold under a single label approved by a regulatory authority, packaged together for sale or shipment as a single unit or sold at a single price, or marketed or sold collectively as a single product (a “Combination
Product”), Net Revenues of such Combination Product for the purposes of determining payments based on Net Revenues hereunder will be calculated by multiplying actual Net Revenues of such Combination Product as determined in the first
paragraph of this Net Revenues definition (“Combination Product Net Revenues”) by the fraction A/(A+B) where A is the Seller’s average Net Revenues price during the period to which the Net Revenues calculation applies for the
Product in such country when sold separately (i.e., without the Other Product) (provided that in the case of Japan, A is the NHI Price during such period) and B is the Seller’s average net revenue (determined in the same manner as
“Net Revenues”) price during the period to which the Net Revenues calculation applies in such country for the Other Product; provided that the average Net Revenues price (or the case of Japan, the NHI Price) in a country for
each Product and the Other Product shall be for a quantity comparable to that used in such Combination Product and of substantially the same formulation and the same route of administration. 

If the net revenue price of the Other Product in a country when sold separately cannot be determined but the Net Revenue price of a Product in
such country when sold separately (i.e., without the Other Product) can be determined, Combination Product Net Revenues for purposes of determining payments based on Net Revenues hereunder will be calculated by multiplying the Combination
Product Net Revenues by the fraction A/C where A is Seller’s average Net Revenues price during the period to which the Net Revenues calculation applies for such Product in such country of a Product in such country (provided that in the case of
Japan, A is the NHI Price during such period) and C is the Seller’s average net revenue (determined in the same manner as “Net Revenues”) price during the period to which the Net Revenues calculation applies in such country for
the Combination Product (provided that in the case of Japan, C is the NHI Price during such period). 
 If the Company, its Affiliates and
Sublicensees do not separately sell a Product or the Other Product in such Combination Product in a country, the Net Revenues attributable to such Combination Product shall be determined by the Parties in good faith based on the relative fair market
value of such Product and such Other Product. If the Parties cannot agree on such relative value, the dispute shall be resolved pursuant to Section 13.5. 
  

	5.	 New definition “NHI Price”. A new defined term “NHI Price” is hereby added to the
License Agreement as a new Section 1.11 as follows: 

 1.11 “NHI Price” means means, with respect to
a Product or Other Product, the National Health Insurance price (yakka) applicable to such Product or Other Product in Japan, which is determined and may be amended from time to time by the Japanese Ministry of

  
 2 

 
Health, Labour and Welfare. Following any National Health Insurance price (yakka) revision with respect to a Product, a new NHI Price for such Product shall be automatically adopted from the day
of the official implementation of such National Health Insurance price (yakka) revision by the Japanese Ministry of Health, Labour and Welfare. 
  

	6.	 Amendment to Section 2.2.    Section 2.2 of the License Agreement
is hereby amended and restated in its entirety as follows: 

 The Company shall be entitled to grant Sublicenses under the
License, on terms and conditions, not inconsistent with terms of this Agreement through multiple tiers upon written notice to the Licensor. The Company expressly understands and agrees that pursuant to the Industrial Technology Enhancement Law of
Japan which is similar to the U.S. Bayh-Dole Act, the Company is required to provide notification to, and obtain acknowledgement and agreement from each sublicensee of each tier of Sublicense of the rights of the Japanese government under such law.
Thus, the Company shall ensure that any Sublicense shall include terms that make the Sublicense dependent on the continued existence of this Agreement and that bind the Sublicensee to observe the relevant material terms of this Agreement. 

 

	7.	 Amendment to Section 13.4. The fourth paragraph of Section 13.4 of the License
Agreement is hereby amended and restated in its entirety as follows: 

 If to Company at; 

Perception Neurosciences, Inc. 

180 Varick Street, Suite 637 

New York, NY 10014 

USA 

Attention: [***] 

Telephone: [***] 

Facsimile: [***] 

Email: [***] 
  

	8.	 No Other Amendments. Except as expressly amended hereby, all of the terms and conditions of the License
Agreement shall remain in full force and effect. 

 [Signature Page Follows.] 

  
 3 

 IN WITNESS WHEREOF, the Parties have executed this Amendment on the day and year first above
written. 
  

									
	PERCEPTION NEUROSCIENCES INC.	 		 	NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY

									
					
	By:	 	 /s/ [***]
	 		 	By:	 	 /s/ [***]

	Name:	 	 [***]
	 		 	Name:	 	 [***]

	Title:	 	  
	 		 	Title:	 	  

	Date:	 	  
	 		 	Date:	 	  

 [Signature Page for Amendment No. [●] to License Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]